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Abstract
Background: Interest is rising in smokeless tobacco as a safer alternative to smoking, but
published reviews on smokeless tobacco and cancer are limited. We review North American and
European studies and compare effects of smokeless tobacco and smoking.
Methods: We obtained papers from MEDLINE searches, published reviews and secondary
references describing epidemiological cohort and case-control studies relating any form of cancer
to smokeless tobacco use. For each study, details were abstracted on design, smokeless tobacco
exposure, cancers studied, analysis methods and adjustment for smoking and other factors. For
each cancer, relative risks or odds ratios with 95% confidence intervals were tabulated. Overall,
and also for USA and Scandinavia separately, meta-analyses were conducted using all available
estimates, smoking-adjusted estimates, or estimates for never smokers. For seven cancers,
smoking-attributable deaths in US men in 2005 were compared with deaths attributable to
introducing smokeless tobacco into a population of never-smoking men.
Results: Eighty-nine studies were identified; 62 US and 18 Scandinavian. Forty-six (52%)
controlled for smoking. Random-effects meta-analysis estimates for most sites showed little
association. Smoking-adjusted estimates were only significant for oropharyngeal cancer (1.36, CI
1.04–1.77, n = 19) and prostate cancer (1.29, 1.07–1.55, n = 4). The oropharyngeal association
disappeared for estimates published since 1990 (1.00, 0.83–1.20, n = 14), for Scandinavia (0.97,
0.68–1.37, n = 7), and for alcohol-adjusted estimates (1.07, 0.84–1.37, n = 10). Any effect of current
US products or Scandinavian snuff seems very limited. The prostate cancer data are inadequate for
a clear conclusion.
Some meta-analyses suggest a possible effect for oesophagus, pancreas, larynx and kidney cancer,
but other cancers show no effect of smokeless tobacco. Any possible effects are not evident in
Scandinavia. Of 142,205 smoking-related male US cancer deaths in 2005, 104,737 are smoking-
attributable. Smokeless tobacco-attributable deaths would be 1,102 (1.1%) if as many used
smokeless tobacco as had smoked, and 2,081 (2.0%) if everyone used smokeless tobacco.
Conclusion: An increased risk of oropharyngeal cancer is evident most clearly for past smokeless
tobacco use in the USA, but not for Scandinavian snuff. Effects of smokeless tobacco use on other
cancers are not clearly demonstrated. Risk from modern products is much less than for smoking.
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Over the last 10 years, interest in smokeless tobacco (ST) as
a possible safer alternative to smoking has risen. Although
a number of recent reviews have considered the evidence
relating ST to cancer, some have not included meta-
analyses [1-3], and others have only provided quantitative
summaries for specific sites: oropharyngeal cancer [4],
pancreatic cancer [5], or oropharyngeal, oesophageal,
pancreatic and lung cancer [6]. No formal comparisons
have been conducted with the well-known effects of
smoking [7,8].
The review described in this paper is restricted to studies
in Western populations. In practice this predominantly
means studies in the USA and Sweden, the only North
American and European countries where the two major
types of ST – chewing tobacco and snuff – are commonly
used [2]. Although ST is also widely used in developing
countries, particularly parts of Central and South-East
Asia, the tobacco is often used in combination with
other products, such as betel nut quid, slaked lime, areca
nut and even snail shells [1,2,9]. This review also does
not consider the limited data on nicotine chewing gum.
Our first objective is to carry out a comprehensive review
of the available epidemiological evidence in Western
countries relating ST to cancer, including meta-analyses
for as many cancer types as the data justify. In meeting
this objective, we take proper account of the potential
confounding role of smoking by distinguishing effect
estimates which are unadjusted for smoking and those
which take smoking into account (either by adjustment
in analyses based on the whole population of smokers
and non-smokers combined or by restricting analysis to
lifelong never smokers). Our second objective is to
provide a quantitative indication of the relative effects of
ST and cigarette smoking.
Methods
Study identification and selection
All reports had to satisfy the following inclusion criteria:
published in a peer reviewed journal or the results publicly
available, epidemiological study in humans, of cohort or
case-control design, study location specified, any form of
cancer as the outcome, and chewing tobacco, oral snuff
or unspecified ST as the exposure. They also had to fall
outside the exclusion criteria: conducted in an Asian or
African population, no control group, or inappropriate
design (case report, qualitative study or review/meta-
analysis). Relevant papers were sought from a MEDLINE
search conducted in May 2008 of “cancer” AND (“smoke-
less tobacco” OR “chewing tobacco” OR “snuff” OR
“snus”), supplemented by citations in recent reviews
[1-6,10] and in the papers obtained.
Data extraction
Reports were grouped by study, and for each study details
were abstracted (see Tables 1 and 2 [11-114]) relating to
the design, period, location, controls used and size, the
exposure (method of assessment, type of ST, exposure
doses and durations considered), the outcome (cancer sites
studied) and issues relating to analysis (type of effect
measure, analysis methods, extent of adjustment for
smoking and other factors, and availability of dose-
response data). The extent of adjustment for smoking for
a study was categorised into five groups: A. no information –
effect estimates are provided but no details are given of
any adjustments made; B. no adjustment – effect estimates
are available for the whole population, but smoking is
not taken into account; C. never smokers – the only effect
estimates available are for never smokers; D. some
adjustment – effect estimates adjusted for smoking are
available, but the adjustment is relatively simple, using two
or three level broad groupings (for example, ever/never
smoked, current/non-current smoker, current/former/never
smoker), and takes no account of daily amount smoked or
duration of smoking; and E. more adjustment – effect
estimates are available that take into account daily amount
smoked, duration of smoking and/or their product (pack--
years). Studies were categorised under D or E if smoking-
adjusted effect estimates are available, regardless of
whether some results for never smokers are also presented.
The method used to adjust for smoking is not always clear.
Studies where the authors merely report that they ‘adjusted
for cigarette smoking’ are included in category D.
Based on the availability of relevant data, 13 cancer
groupings (oropharyngeal, oesophagus, stomach, pancreas,
other digestive, larynx and nasal, lung, prostate, bladder,
kidney, haematopoietic and lymphoid, other and all), were
selected, with results for each grouping tabulated in a
standard way, with details given of the source, exposure to
ST, smoking group, sex, number of cases and adjustment
factors for each effect estimate or indication of association
(see tables dealing with individual effects estimates,
below). For each study the intent is to extract the relative
risk (RR) or odds ratio (OR) adjusted for the most factors,
relevant to current, former or ever exposure to chewing
tobacco, snuff or overall/undefined ST. Where relevant
results for a study are reported in more than one paper,
those based on the greatest number of cases are used.
Results are included, where available, for the whole
population and for never smokers, and for sexes separately.
RR or OR estimates based on zero exposed cases (or
controls) are not included as providing too little informa-
tion and because a valid confidence interval (CI) cannot be
calculated. Suitable estimates of effect (RR or OR) and
precision (CI) provided by the authors are used if possible,
estimates otherwise being calculated from available data
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(page number not for citation purposes)Table 1: Cohort studies of smokeless tobacco and cancer
Study Country Follow-up period Baseline population Exposure
a Reference
b Cancers studied (cases)
c
Lutheran Brotherhood
cohort
d
USA 1966 to 1986 17,633 white men aged 35+ years ST Hsing et al. 1990 [11] Prostate (149)
Kneller et al. 1991 [12] Stomach (75)
Zheng et al. 1993 [13] Pancreas (57)
US Veterans cohort
e USA 1954/57 to 1980 248,046 US veterans aged 31–84 years,
over 99.5% men
ST Hsing et al. 1991 [15] Prostate (4,607)
Heineman et al. 1992 [16] Multiple myeloma (582)
f
Zahm et al. 1992 [17] Soft tissue sarcoma (119), pharynx (55), buccal cavity
(74)
Heineman et al. 1995 [18] Colon (3,812), rectum (1,100)
Iowa cohort USA 1986/89 to 1995 1,572 men aged 40+ years, controls in a
case-control study
ST Putnam et al. 2000 [20] Prostate (101)
f
NHANES I follow-up
cohort
g
USA 1971/75 to 2002 14,407 adults aged 25–74 years
h ST Accort et al. 2002 [21] All, lung
i
Accort et al. 2005 [22] All, lung, breast, digestive, oral, prostate
f, i
CPS-I
j USA 1959 to 1972 77,407 never smoking men aged 30+
years from 25 states
ST Henley et al. 2005 [23] All (2,332), oral (13), digestive (913), lung (134),
genitourinary (559)
CPS-II
k USA 1982 to 2000 114,809 never smoking men aged 30+
years nationwide
ST
l Henley et al. 2005 [23] All (6,140), oral (46), digestive (1,999), lung (400),
genitourinary (1,709), haematopoietic (923)
1982 to 1996 467,788 men aged 30+ years nationwide ST Chao et al. 2002 [24] Stomach (996)
Norway cohorts
m Norway 1966 to 2001 10,136 men from two cohorts, a sample
of the 1960 census and relatives of
Norwegian migrants to the USA
Snuff Boffetta et al. 2005 [26] Oral (34), oesophagus (27), stomach (217), pancreas
(105), lung (343), kidney (88), bladder (239)
n
Swedish construction
workers
Sweden 1974 to 1985 135,036 men Snuff Bolinder et al. 1994 [28] All (1,269), lung (204)
1971 to 2000 337,311 men Odenbro et al. 2005 [29] Cutaneous squamous cell carcinoma (756)
f
1971 to 2000 335,612 adults, over 99.3% men Fernberg et al. 2006 [30] Malignant lymphoma (1,514)
f
1971 to 2004 336,381 men Fernberg et al. 2007 [31] Leukaemia (372), multiple myeloma (520)
f
1978 to 2004 279,897 men Luo et al. 2007 [32] Oral (248), lung (2,198), pancreas (448)
f
1971 to 2004 339,802 men Odenbro et al. 2007 [33] Melanoma (1,639)°
1971 to 2004 336,381 men Zendehdel et al. 2008 [34] Stomach (1,385), oesophagus (366)
f
Uppsala County cohort Sweden 1973/74 to 2002 9,976 men Snuff Roosaar et al. 2008 [35] All (1,572), smoking-related (493), oral (34)
p
aOnly exposures for which results are available are shown.
bMain references. Other references supplying limited data are indicated in footnotes.
cNumbers of cases are totals for the sexes specified. Numbers of cases exposed to ST are shown in the tables presenting results by site. Cases are deaths, unless indicated. Oral is used as an abbreviation for oropharnyx.
dSome limited additional results for the Lutheran Brotherhood cohort, based on follow-up to 1981, were reported earlier for cancers of the prostate, pancreas and oesophagus in IARC Monograph 37 in 1985 [14].
eSome limited additional results for the US Veterans cohort, based on follow-up from 1954 to 1969 were presented earlier for a range of cancers in an abstract by Winn et al. in 1982 [19].
fCancers listed are incident cases.
gNHANES I = First National Health and Nutrition Examination Survey.
hData on ST use were only collected in 3,847 subjects at baseline in 1971–1975, but were collected for all subjects in follow-up surveys in 1982–1984. 6,805 subjects were considered in the mortality analyses [21] and
7,779 in the incidence analyses [22].
iNumbers of cases not given.
jCPS-I = Cancer Prevention Study I.
kCPS-II = Cancer Prevention Study II. Some additional results for lung cancer, based on mortality to 2002, comparing 111,952 men who quit cigarette smoking with 4,443 who switched to ST, were presented by Henley
et al. in 2007 [25].
lResults for chewing and snuff are also given for all cancers and lung cancers.
mSome limited additional results, based on follow-up to 1978, were reported by Heuch et al. in 1983 [27] for pancreatic cancer incidence and in IARC Monograph 37 in 1985 [14] for cancers of the buccal cavity/pharynx,
oesophagus, pancreas and prostate.
nCancers listed include incident cases.
°Includes cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma.
pNumbers are incident cases. An analysis of overall cancer based on 1,574 deaths was also conducted.
ST = smokeless tobacco.
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)Table 2: Case-control studies of smokeless tobacco and cancer
Study Country Study period
a Controls
a Sex
b Exposures studied
c Cancers studied (cases)
d
Broders 1920 [37] USA NA Hospital M+F Chew, snuff, ST Oral (537)
Doll and Hill 1952 [38] UK 1948–1952 Hospital M Chew, snuff Lung (1,209)
Moore et al. 1953 [39] USA 1951–1952 Hospital M ST Oral (112), face (93)
Wynder et al. 1957 [40] Sweden 1952–1955 Hospital M Chew Oral (166), oesophagus (39),
larynx (60)
Wynder and Bross 1957 [41] USA NA Hospital M Chew Oral (543)
Peacock et al. 1960 [42] USA 1952–1958 Hospital M+F ST Oral (45)
Lockwood 1961 [43] Denmark 1942–1956 Population M+F ST Bladder (282)
Wynder and Bross 1961 [44] USA 1956–1959 Hospital M Chew Oesophagus (150)
Vogler et al. 1962 [36] USA 1956–1957 Hospital M+F Chew, snuff Oral (228)
Vincent and Marchetta 1963 [45] USA NA Hospital M Snuff Oral (66), larynx (23)
Wynder et al. 1963 [46] USA 1957–1960 Hospital M Chew, snuff, ST Bladder (300)
Bennington and Laubscher 1968
[47]
USA 1951–1956 Hospital M Chew Kidney (88)
Dunham et al. 1968 [48] USA 1958–1964 Hospital M+F ST Bladder (493)
Martinez 1969 [49] Puerto Rico 1966 Hospital,
population
M+F Chew Oral (221), oesophagus (179)
Keller 1970 [50] USA 1958–1962 Hospital M ST Oral (314)
Cole et al. 1971 [51] USA 1967–1968 Population M+F Chew, snuff Bladder (470)
Bjelke et al. 1974 [52] USA NA NA NA Chew Colorectal (373), oesophagus
(52), stomach (83)
Norway NA NA NA Chew Colorectal (278), stomach (228)
Armstrong et al. 1976 [53] UK 1972–1974 Hospital M ST Kidney (96)
Browne et al. 1977 [54] UK 1957–1971 Population M+F Chew Oral (75)
Williams and Horm 1977 [55] USA 1969–1971 Hospital M+F ST Many types (7,518)
e
Wynder and Stellman 1977 [56] USA 1969–1975 Hospital M Chew, snuff, ST Oral (593), bladder (589), larynx
(387), lung (1,051), oesophagus
(183)
Engzell et al. 1978 [57] Sweden 1961–1971 Population M Snuff Nose (36)
Howe et al. 1980 [58] Canada 1974–1976 Population M Chew Bladder (480)
Westbrook et al. 1980 [59] USA 1955–1975 Hospital F Snuff Oral (55)
Pottern et al. 1981 [60] USA 1975–1977 Decedent M Chew, snuff Oesophagus (120)
Winn et al. 1981 [61] USA 1975–1978 Hospital F Snuff Oral (255)
Mommsen and Aagaard 1983 [62] Denmark 1977–1980 Population M Chew Bladder (165)
Wynder et al. 1983 [63] USA 1977–1980 Hospital M Chew, snuff, ST Oral (414)
Brinton et al. 1984 [64] USA 1970–1980 Hospital,
decedent
M+F Chew, snuff, ST Nose (160)
McLaughlin et al. 1984 [65] USA 1974–1979 Population M Chew, snuff, ST Kidney (313)
Hartge et al. 1985 [66] USA 1977–1978 Population M Chew, snuff, ST Bladder (2,240)
Weinberg et al. 1985 [67] USA 1978–1980 Decedent,
population
M Chew Stomach (178)
Goodman et al. 1986 [68] USA 1977–1983 Hospital M+F Chew Kidney (267)
Kabat et al. 1986 [69] USA 1976–1983 Hospital F Snuff Bladder (152)
Stockwell and Lyman 1986 [70] USA 1982 Population M+F ST Oral (1,462), nose (92), larynx
(161)
Young et al. 1986 [71] USA 4 yr period Hospital M+F ST Oral (317), larynx (179)
Lindquist et al. 1987 [72] Sweden 1980–1983 Population M Snuff Leukaemia (76)
Asal et al. 1988 [73] USA 1981–1984 Hospital,
population
M Snuff Kidney (209)
Blot et al. 1988 [74] USA 1984–1985 Population M+F ST Oral (1,114)
Falk et al. 1988 [75] USA 1979–1983 Hospital M+F Chew, snuff Pancreas (363)
Morris Brown et al. 1988 [76] USA 1982–1984 Population M ST Oesophagus (207)
Slattery et al. 1988 [77] USA 1977–1983 Population M Chew, snuff, ST Bladder (332)
Spitz et al. 1988 [78] USA 1985–1987 Hospital M+F Chew, snuff, ST Oral (185)
f
Burch et al. 1989 [79] Canada 1979–1982 Population M Chew, snuff Bladder (627)
Franco et al. 1989 [80] Brazil 1986–1988 Hospital M+F ST Oral (232)
Zahm et al. 1989 [81] USA 1976–1982 Population M ST Soft tissue sarcoma (133)
Farrow et al. 1990 [82] USA 1982–1986 Population M Chew Pancreas (148)
Blomqvist et al. 1991 [83] Sweden NA Hospital M+F Snuff Oral (61)
Ghadirian et al. 1991 [84] Canada 1984–1988 Population M+F Chew Pancreas (179)
Maden et al. 1992 [85] USA 1985–1989 Population M ST Oral (131)
Marshall et al. 1992 [86] USA 1975–1983 Population M+F Chew Oral (290)
Morris Brown et al. 1992 [87] USA 1981–984 Population M ST Leukaemia (578)
Morris Brown et al. 1992 [88] USA 1981–1984 Population M ST Non-Hodgkin's lymphoma (622)
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[115-118] summarised elsewhere [4]. Where an effect
estimate cannot be calculated, statements made by the
authors are summarised into terms such as ‘no association’
or ‘no significant association’. Data are summarised for all
types of cancer, except those relating to subdivision by type
within site (for example, adenocarcinoma or squamous
cell carcinoma of the lung, or t(14; 18)-positive and –
negative non-Hodgkin’s lymphoma or those relating to
combined ‘other’ groups of cancers, which typically vary in
definition from study to study).
Data presentation
Study-specific results for the different types of cancer are
presented in an essentially identical format, with a
standard set of information included for each effect
estimate included. Points to note about the entries in the
various columns are discussed below.
Source
For the case-control studies, the source reference is
shown. For the cohort studies, the source reference is
also shown, but the study is also identified by name.
Table 2: Case-control studies of smokeless tobacco and cancer (Continued)
Sterling et al. 1992 [89] USA 1986 Population M+F Snuff, ST All cancer (459,792), oral (6,976),
all digestive (109,514)
Mashberg et al. 1993 [90] USA 1972–1989 Hospital M Chew, snuff, ST Oral (359)
Perry et al. 1993
g USA About 1992 Hospital M+F ST Oral (133)
Spitz et al. 1993 [92] USA 1987–1991 Hospital M+F Chew Oral (108)
f
Chow et al. 1994 [93] USA 1985–1997 Population M Chew Bile duct (49)
Hansson et al. 1994 [94] Sweden 1989–1992 Population M+F Chew, snuff Stomach (338)
Hardell et al. 1994 [95] Sweden 1974–1978 Population M Snuff Non-Hodgkin's lymphoma (105)
Hayes et al. 1994 [96] USA 1986–1989 Population M Chew, snuff, ST Prostate (981)
Kabat et al. 1994 [97] USA 1977–1990 Hospital M+F Chew, snuff Oral (1,560)
Bundgaard et al. 1995 [98] Denmark 1986–1990 Population M+F Chew Oral (161)
McLaughlin et al. 1995 [99] 5 countries
h 1989–1991 Population M+F ST Kidney (1,732)
Muscat et al. 1995 [100] USA 1977–1993 Hospital M Chew Kidney (543)
Muscat et al. 1997 [101] USA 1985–1993 Hospital M Chew, snuff Pancreas (290)
Lewin et al. 1998 [102] Sweden 1980–1989 Population M Snuff Oral (266), larynx (157),
oesophagus (122)
Muscat and Wynder 1998 [103] USA 1977–1980 Hospital M+F Chew, ST Oral (128)
Schildt et al. 1998 [104] Sweden 1980–1989 Population M+F Chew, snuff, ST Oral (410)
Schwartz et al. 1998 [105] USA 1990–1995 Population M ST Oral (165)
Yuan et al. 1998 [106] USA 1986–1994 Population M+F ST Kidney (1,204)
Ye et al. 1999 [107] Sweden 1989–1995 Population M+F Chew, snuff Stomach (514)
Lagergren et al. 2000 [108] Sweden 1995–1997 Population M+F Snuff Oesophagus (189), stomach (429)
Zheng et al. 2001 [109] USA NA Population M+F Chew, snuff Brain (375)
Schroeder et al. 2002 [110] USA 1980–1982 Population M Chew, snuff, ST Non-Hodgkin's lymphoma (182)
Alguacil and Silverman 2004 [111] USA 1986–1989 Population M+F ST Pancreas (526)
Bracci and Holly 2005 [112] USA 1988–1993 Population M ST Non-Hodgkin's lymphoma (725)
Rosenquist et al. 2005 [113] Sweden 2000–2004 Population M+F Snuff Oral (132)
Hassan et al. 2007 [114] USA 2000–2006 Hospital M+F Chew, snuff, ST Pancreas (808)
aNA = not available.
bM = male, F = female, M+F = both sexes. Studies of both sexes with results reported only for males are shown as M.
cOnly exposures for which results are available are shown.
dOral (oropharyngeal) is defined as in Weitkunat et al. 2007 [4] to include any of the following sites: buccal mucosa, floor of mouth, gingival, gum/
palate, lip, oral cavity/mouth, pharynx/alveolus, tongue, tonsils, salivary glands and oral unspecified. This reference also shows the actual sites
included for most of the studies included here. For other cancers, more precise definitions of site or histology are given, where relevant, in the tables
presenting the findings. Numbers of cases are totals for the sexes specified. Numbers of cases exposed to STare shown in the tables presenting results
by site.
eResults were presented for the following 'known tobacco-related' sites: oral (298 cases), oesophagus (72), larynx (119), lung (931) and bladder (306),
with comparisons made with all other 'non-related' sites. Results were also presented for various non-related sites: stomach (266), small intestine( 1 9 ) ,
colon (722), rectum (339), liver (45), gall bladder/bile duct (81), pancreas (224) breast (1,177), cervix (266), uterus (38), ovary (180), vulva (31),
prostate (531), male genitalia (53), kidney (126), connective tissue (84), melanoma (99), nervous system (136), thyroid gland (94), lymphosarcoma
(121), Hodgkin's disease (84), other lymphomas (33), multiple myeloma (86), leukaemia (172) and other or unknown primaries (385), with
comparisons made with all other non-related sites combined.
fIncludes larynx cancer.
g"Attributable oral cancer risk due to smokeless tobacco use based on a case-control study at Sinai Hospital in Detroit"; Perry et al., unpublished.
Cited by Gross et al. 1995 [91].
hAustralia, Denmark, Germany, Sweden and USA.
ST = smokeless tobacco.
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The exposure is identified as chewing tobacco (’chew’),
‘snuff’ or smokeless tobacco (’ST’). ST implies the results
relate to smokeless tobacco unspecified by the author, or
to use of either chewing tobacco or snuff or both.
ST use – exposure
Results are presented for current, former or ever use, or
simply for ‘use’ where the timing of exposure was
unspecified by the author. For current, former or ever
use, the comparison is with never use; for use, it is with
non-use.
Smoking
Results are presented only for any smoking (that is,
based on the combined population of ever and never
smokers) and for never smokers.
Sex
Results are shown, where available, for the sexes
separately, though in some studies results are given
only for the sexes combined.
RR/OR id
Within each table, each effect estimate (RR or OR) is
given a unique identification number, so that those
which are included in specific meta-analyses can readily
be seen.
Cases
The number of ST-exposed cases is shown. Total
numbers of cases are given elsewhere. Estimates are not
presented unless there is at least one exposed case.
Estimate (95% CI)
This is the RR for cohort studies or the OR for case-
control studies, together with its 95% CI. For many
studies, the estimates are not given directly in the source
paper, but were calculated from data provided. This
involved one or more of the following: estimating
numbers of exposed and unexposed cases and controls
from proportions exposed given numerically or graphi-
cally and, where appropriate, combining numbers over
level of exposure or cancer subtype; calculating estimates
f r o ma2×2t a b l e ,o rm u l t i p l ei n d e p e n d e n t2×2t a b l e s
using standard methods [115], and calculating estimates
from non-independent RR/ORs by level of exposure or
by cancer type using the method of Hamling et al. 2007
[118]. Fuller details of the method of calculation used
for each estimate are available on request. In a limited
number of studies, as indicated in the tables, estimates
were available separately for chewing tobacco and for
snuff, but data were lacking for joint use. Here estimates
for combined ST use were calculated assuming that no
one used both chewing tobacco and snuff. Where there is
a choice of relevant estimates from a study, preference is
given to the estimate adjusted for the most potential
confounding factors, and, for cohort studies, the
estimate from the publication with a longer follow-up
period.
Adjustment factors
The adjustment factors used for each estimate are shown.
For matched case-control studies, the matching factors
are not included unless the estimate specifically took this
into account (for example, by conditional logistic
regression). The factors used have been simplified into
a relatively short consistent list, rather than repeating
verbatim the wide variety of variable descriptions given
by the original authors. Thus ‘res’ (area of residence)
includes any variable based on the location of the subject
and, for example, includes centre in multicentre case-
control studies. ‘Diet’ includes any aspect of diet, and
‘alc’ (alcohol) any aspect of alcohol use. Estimates
relevant to never smokers are not listed as being adjusted
for smoking (’smok’).
Layout
For the five columns, ST use – type, ST use – exposure,
smoking, sex and adjustment factors, any blank entry for
a particular effect estimate is assumed to be the same as
in the first previous non-blank entry in that column. This
avoids needless repetition and makes the tables easier to
read.
Meta-analysis
Estimates with no CI are not included in the meta-
analyses. The standard error of the logarithm of
estimates of effect size was calculated from its reported
or estimated CI, assuming that the effect size was log-
normally distributed. The logarithms of the effect sizes
and their corresponding standard errors form the data
points for fixed-effect and random-effects meta-analysis
[116].
For most cancer groupings, results of nine random-effect
meta-analyses are presented, subject to availability of
data (see tables summarising meta-analysis results,
below). In the first set of three, any, there is no restriction
of estimates on type of exposure or region. In the second
set, any ST use (USA), estimates are restricted to those
from studies conducted in the USA (or on occasion in
Puerto Rico), while in the third set, snuff (Scandinavia),
estimates are restricted to those for snuff and for studies
conducted in Scandinavia. Each of the three sets of meta-
analyses is divided into overall data, smoking-adjusted and
never smokers.I nt h eoverall data analyses, estimates are
not restricted on smoking status or on adjustment for
BMC Medicine 2009, 7:36 http://www.biomedcentral.com/1741-7015/7/36
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(page number not for citation purposes)smoking. The smoking-adjusted analyses only include
estimates that are for the whole population and adjusted
for smoking or are for never smokers. The never smokers
analyses are restricted to estimates for never smokers. For
oropharyngeal cancer, where more estimates are avail-
able, some additional meta-analysis results are shown,
based on estimates that are smoking and alcohol
adjusted, and on estimates published since 1990.
To avoid double-counting multiple non-independent
estimates from the same study, estimates from each
study are selected for inclusion in the meta-analyses
using order of preference lists for ST exposure (ever use/
unspecified use/current use/former use), then smoking
status (any – based on the combined population of
smokers and non-smokers/never smokers), and then ST
type (ST/snuff/chew), with each list being in order of
most to least preferred. At each step we retain those
estimates highest up the list, discarding any estimate
lower in the preference order. If the procedure ends up
with separate estimates for males and for females, both
are included in the analysis. In one study [36], the results
available are for males for chewing and for females for
snuff (see Table 3). Although the procedure, strictly
applied, selects only the snuff estimate, it was decided to
include both in the relevant meta-analyses.
The presentation of the meta-analyses shows the number
of estimates combined; the identification numbers of these
estimates (so that they can be related to the preceding table
of individual effect estimates); the combined random-
effects estimate, with its 95% CI [116], the chi-squared and
P value of homogeneity [119] and the I
2 statistic [120]. The
meta-analyses conducted also include a test for publication
bias [121] where five or more estimates are combined.
Findings significant at P < 0.1 are indicated.
Forest plots are also included for most of the cancers.
These are generally based on the smoking-adjusted
analyses, with the estimates split by region and shown
with cohort data first, then case-control, presented in
order of publication year.
Sensitivity analysis
For each estimate included, the value of Q
2 is calculated
by w (x - x )
2,w h e r ew is the inverse-variance weight, x is
the logarithm of the effect size and x its mean. Q
2 is the
contribution of the estimate to the heterogeneity chi-
squared statistic [116]. Where there is significant
(P < 0.05) heterogeneity of estimates, sensitivity to
potentially outlying estimates is tested by removing that
with the largest Q
2 value and rerunning the analyses.
This process is continued until there is no longer
significant heterogeneity.
Sensitivity to the criterion for including estimates based
on ST exposure is also tested by rerunning the meta-
analyses with the preference list for ST exposure changed
from ever use/unspecified use/current use/former use to
current use/ever use/unspecified use/former use.
Meta-regression analysis
For oropharyngeal cancer, fixed-effects regression analy-
sis is used to investigate how the estimates selected for
the first set of meta-analyses vary by region (USA;
Scandinavia; other), period × study type (cohort; case-
control published before 1990; case-control published
after 1990), sex (male; female; combined), ST exposure
(ever or unspecified use; current use), smoking (any,
adjusted for smoking; any, unadjusted for smoking;
never) and alcohol adjustment (yes; no). For those other
cancers where more than five estimates are available and
where there was evidence of significant (P < 0.05)
heterogeneity, the meta-regression analyses use a more
limited variable list: region, sex, and smoking as above,
and also study type (cohort; case-control).
Regression analyses are only conducted based on the
overall data and smoking-adjusted data. The analyses
successively introduce the most significant factor into the
model, stopping when no further factor significant at
P < 0.05 can be added. Significance is estimated by
treating the ratio of the deviance per degree of freedom
(d.f.) explained by the factor to the residual deviance per
d.f. as an F statistic. For oropharyngeal cancer some
additional analyses investigate the drop in deviance
resulting from introducing each factor individually, and
others are conducted having excluded ‘outlying’ observa-
tions with a very high Q
2 value.
Estimating deaths attributable to smoking
RRs for current and former cigarette smokers (compared
with never cigarette smokers) for men aged 35+ for seven
major cancers caused by smoking (lip/oral cavity/
pharynx, oesophagus, pancreas, larynx, lung, bladder,
kidney/other urinary organs) were obtained from the
American Cancer Society Cancer Prevention Study II
(CPS-II) [122]. Numbers of deaths for these seven
cancers occurring in US men aged 35+ in 2005 were
obtained from WHO [123]. Estimates of the proportion
of current and former cigarette smokers in US men aged
35+ in 2005 were obtained from the National Health
Interview Survey [124].
Defining Di as the numberof deathsforcanceri (i= 1,...,7),
Rci and Rfi as the RRs for current and former cigarette
smokers for cancer i, and pc and pf as the proportions of
current and former cigarette smokers in the population, the
estimated number of deaths, Di
∗, that would have occurred
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(page number not for citation purposes)Table 3: Oropharyngeal cancer; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI) Adjustment factors
e
Cohort studies
US Veterans: Zahm et al. 1992 [17] ST Ever Any M
f 1 129 4.11 (2.90–5.84)
g age, time
CPS-I: Henley et al. 2005 [23] ST Current Never M 2 4 2.02 (0.53–7.74) age, alc, asp, bmi, diet, edu,
exer, occ, race
CPS-II: Henley et al. 2005 [23] ST Current Never M 3 1 0.90 (0.12–6.71) age, alc, asp, bmi, diet, edu,
exer, occ, race
Norway Cohorts: Boffetta et al. 2005
[26]
Snuff Current Any M 4 6 1.13 (0.45–2.83) age, smok
Former 5 3 1.04 (0.31–3.50)
Ever 6 9 1.10 (0.50–2.41)
Swedish construction workers: Luo et al.
2007 [32]
Snuff Ever Any M 7 NA 0.70 (0.50–0.90) age, bmi, smok
Current Never 8 9 0.90 (0.40–1.80) age, bmi
Former 9 1 0.70 (0.10–5.00)
Ever 10 10 0.80 (0.40–1.70)
Uppsala County: Roosaar et al. 2008 [35] Snuff Ever Any M 11 11 3.10 (1.50–6.60) age, alc, res, smok, time
Never 12 5 2.30 (0.70–8.30) age, alc, res, time
Case-control studies
Broders 1920 [37] Chew Use Any M+F 13 128 2.05 (1.48–2.83)
g smok
Snuff 14 2 1.76 (0.12–26.52)
g none
ST 15 130 2.05 (1.48–2.83)
g
Moore et al. 1953 [39] ST Use Any M 16 65 3.00 (1.37–6.54)
g none
Wynder et al. 1957 [40] Chew Ever Any M 17 NA no association
h none
Wynder and Bross 1957 [41] Chew Ever Any M 18 91 2.00 (1.16–3.47)
g smok
Peacock et al. 1960 [42] ST Use Any M 19 14 3.06 (1.08–8.63)
g age, ins
F 20 11 2.00 (0.66–6.01)
g
Vogler et al. 1962 [36] Chew Ever Any M 21 46 7.38 (4.31–12.62)
g none
Snuff F 22 54 38.28 (21.49–68.15)
g
Vincent and Marchetta 1963 [45] Snuff Use Any M 23 12 4.22 (1.41–12.63)
g none
Martinez et al. 1969 [49] Chew Use Any M 24 4 2.29 (0.62–8.48)
g none
F 25 1 0.34 (0.04–2.79)
g
Keller 1970 [50] ST Use Any M 26 11 3.63 (1.02–12.95)
g smok
Never 27 4 3.04 (0.62–14.99)
g
Browne et al. 1977 [54] Chew Use Any M+F 28 7 0.67 (0.27–1.66)
g none
Williams and Horm 1977 [55] ST Ever Any M 29 16 0.91 (0.53–1.56)
g none
F 30 2 1.54 (0.37–6.42)
g
Wynder and Stellman 1977 [56] Chew Ever Any M 31 10 0.62 (0.32–1.21)
g none
Snuff 32 61 1.15 (0.85–1.55)
g
ST 33 71 1.02 (0.78–1.34)
i
Westbrook et al. 1980 [59] Snuff Ever Any F 34 50 540.00 (60.97–4782.82)
g none
Winn et al. 1981 [61] Snuff Ever Any F 35 107 2.67 (1.83–3.90)
g race, smok
Wynder et al. 1983 [63] Chew Ever Any M 36 37 1.00 (0.62–1.61)
g none
Snuff 37 12 0.42 (0.11–1.65)
g
ST 38 49 0.90 (0.57–1.41)
i
Stockwell and Lyman 1986 [70] ST Ever Any M+F 39 11 2.02 (1.01–4.02)
g none
Young et al. 1986 [71] ST Ever Any M 40 NA no association none
Blot et al. 1988 [74] ST Ever Any M 41 46 0.85 (0.57–1.26)
g none
F 42 11 3.44 (1.09–10.91)
g
Never F 43 6 6.20 (1.90–19.80) age, race, res, resp
Spitz et al. 1988 [78] Chew Ever Any M+F 44 23 1.00 (0.54–1.85)
g none
Snuff 45 9 3.40 (1.00–10.90)
ST 46 25 1.05 (0.57–1.91)
g
Franco et al. 1989 [80] ST Use Any M+F 47 9 1.40 (0.59–3.33)
g none
Blomqvist et al. 1991 [83] Snuff Ever Never M+F 48 2 0.67 (0.08–5.75)
g none
Maden et al. 1992 [85] ST Ever Any M 49 19 4.50 (1.50–14.30) age
Marshall et al. 1992 [86] Chew Use Any M 50 NA no significant association none
Sterling et al. 1992 [89] ST Ever Any M+F 51 28
g 1.04 (0.41–2.68)
g age, alc, occ, race, sex, smok
Snuff Ever Any M+F 52 NA 2.42 (1.28–4.59) age, race, sex
Mashberg et al. 1993 [90] Chew Ever Any M
f 53 NA 1.00 (0.70–1.40) age, alc, race, smok
Snuff 54 NA 0.80 (0.40–1.90)
ST 55 52 0.96 (0.70–1.33)
i
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estimated by:
DD p R p R ii c c i f f i
∗ =+ − +− /( ( ) ( )) 11 1
The number of deaths avoided from these seven cancers,
had the whole population the risk of never smokers (that
is, the deaths attributable to smoking) is then estimated by:
E( D D ) ii
i1
7
=−
∗
= ∑
Estimating deaths attributable to ST in a population
of never smokers
Let us further define Rsi as the estimated relative risk
from ST for cancer i based on the meta-analyses using
smoking-adjusted effect estimates. Where Rsi is estimated
to be less than 1, it is taken to be 1 for the purposes of
calculating deaths attributable to ST.
For a population of never smokers, the number of deaths
from cancer i that would have occurred had the same
proportion of men used ST as had ever smoked is then
estimated by:
DD p p R ii c f s i
∗∗ ∗ =+ + − ( ( )( )) 11
The increase in overall deaths from these seven cancers is
then given by:
I( D D ) ii
i1
7
1 =−
∗∗ ∗
= ∑
I1 c a nt h e nb ec o m p a r e dw i t hEa sa ni n d i c a t o ro ft h e
relative effects of ST and smoking.
Also for a population of never smokers, the number of
deaths from cancer i that would have occurred had all
the men used ST, is estimated by:
DD R ii s i
∗∗∗ ∗ =
Table 3: Oropharyngeal cancer; individual effect (relative risk/odds ratio) estimates (Continued)
Perry et al. 1993
j ST Use Any M+F 56 10 1.43 (0.64–3.21)
g age, alc, occ, race, sex, smok
Spitz et al. 1993 [92] Chew Use Any M+F 57 NA 1.20 (not significant) none
Kabat et al. 1994 [97] Chew Ever Any M 58 67 1.11 (0.81–1.53)
g smok
Snuff Ever Never M+F 59 4 4.79 (1.19–19.30)
g none
Bundgaard et al. 1995 [98] Chew Ever Any M+F 60 8 1.44 (0.59–3.51)
g none
Lewin et al. 1998 [102] Snuff Current Any M 61 18 0.84 (0.47–1.50)
g a g e ,a l c ,r e s ,s m o k
Former 62 22 1.28 (0.70–2.35)
g
Ever 63 40 0.98 (0.63–1.50)
g
Muscat et al. 1998 [103] Chew Ever Any M+F 64 3 0.89 (0.18–4.49)
g none
ST 65 4 1.19 (0.26–5.45)
i
Schildt et al. 1998 [104] Chew Use Any M+F 66 5 0.60 (0.20–2.00) age, sex, res
Snuff Current 67 39 0.70 (0.40–1.10)
Former 68 28 1.50 (0.80–2.90)
Ever 69 67 0.80 (0.50–1.30) age, alc, sex, smok, res
Current Never 70 19 0.70 (0.40–1.20) age, sex, res
Former 71 9 1.80 (0.90–3.50)
Ever 72 28 1.01 (0.64–1.57)
g
ST Ever Any 73 72 0.87 (0.61–1.25)
i none
Schwartz et al. 1998 [105] ST Ever Any M 74 NA 1.00 (0.40–2.30) age, alc, smok
Rosenquist et al. 2005 [113] Snuff Current Any M+F 75 13 1.10 (0.50–2.50) alc, smok
Former 76 7 0.30 (0.10–0.90)
Ever 77 20 0.70 (0.30–1.30)
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 4, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eAbbreviations used: alc = alcohol, asp = aspirin, bmi = body mass index, edu = education, exer = exercise, ins = insurance status, occ = occupation,
res = area of residence, resp = respondent, smok = smoking.
fThe population included < 0.5% females.
gRR/OR and/or 95% CI estimated from data provided in the source.
hThe average ridit duration of chewing did not differ significantly from the controls for any type of oral cancer.
iRR/OR and/or 95% CI estimated from data provided in the source assuming that no one both chewed and used snuff.
j"Attributable oral cancer risk due to smokeless tobacco use based on a case-control study at Sinai Hospital in Detroit", Perry et al., unpublished. Cited
by Gross et al. 1995 [91].
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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7
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∗∗∗∗ ∗
= ∑
Results
The MEDLINE search identified 690 publications. Two
hundred and thirty-eight were rejected as describing
studies conducted in Asia or Africa or relating to
products typically used there, 96 as not describing
epidemiological studies, 112 as not relating to cancer
and 163 as being reviews, letters or comments not
providing primary data. Seventeen were rejected as
having an inappropriate study design and three as not
providing relevant results. This left 61 apparently
relevant publications. Taking into account also citations
in recent reviews [1-6,10], and eliminating publications
that referred to studies more recently or completely
covered in other publications, a total of 104 publications
were considered. Twenty-five related to nine cohort
studies, and 79 to 80 case-control studies. Fuller details
o ft h es e a r c ha r eg i v e ni nF i g u r e1 ,w h i l s tt h es t u d i e sa n d
publications considered are presented in the following
two sections.
Cohort studies
Results relating ST use to mortality or incidence have
been reported for nine cohort studies, with results
provided by multiple publications for some studies. Six
studies have been conducted in the USA and are based
on the Lutheran Brotherhood cohort [11-14], the US
Veterans cohort [15-19], the Iowa cohort [20], the First
National Health and Nutrition Examination Survey
(NHANES I) Follow-up cohort [21,22], and the Amer-
ican Cancer Society Cancer Prevention Study I (CPS-I)
[23] and Study II (CPS-II) [23-25]. One study was based
on two Norway cohorts [14,26,27] while the remaining
two were conducted in Sweden; one based on construc-
tion workers [28-34], and the other on a cohort in
Uppsala County [35]. Fuller details of these studies are
given in Table 1. A number of these studies (US Veterans,
CPS-I, CPS-II, Swedish Construction Workers) are
extremely large, involving at least 100,000 subjects,
though the number of ST users is less than this,
690 publications identified as 
potentially relevant by MEDLINE 
search 
629 publications excluded for following reasons 
 238  Asian or African studies (or ST products) 
  96  not epidemiological  studies (27 animals 
experimental, 69 human laboratory) 
 112  not cancer studies (17 of precancerous lesions, 
75 of tobacco prevalence/cessation, 20 other) 
 141  reviews (34 of ST and cancer, 107 other) 
  22  letters and comments providing no new data 
  17  studies of inappropriate design (9 case report, 
    6 ecological, 1 cross-sectional, 1 other) 
  3  studies giving no relevant results on ST 
61 relevant publications identified after 
exclusions
45 additional relevant publications from other major 
reviews or from citations in publications identified 
2 (of the 61) identified publications excluded where 
results from a further publication gives more up-to-date 
or fuller results 
104 publications used for review 
and meta-analyses 
9 cohort studies 
(25 publications) 
80 case-control studies 
(79 publications) 
Figure 1
Flow chart for search strategy for review of literature on smokeless tobacco and cancer. The flow chart shows the
number of publications identified by the MEDLINE search, and the number excluded by reason. The number of additional
publications identified from reviews and secondary references is also indicated, as is the total number of publications
considered in the review and meta-analysis, subdivided by study type.
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analyses of Henley et al. [23] restricted attention to never
smokers of cigarettes. The US studies generally present
results for combined ST use, the main exception being
the analyses of CPS-II [23] where some separate analyses
are presented for snuff and chewing tobacco. The results
from the Swedish studies relate to snuff use, as do the
main results from the Norwegian study [26].
Case-control studies
Results relating ST use to cancer have been reported for 80
case-control studies, with Table 2 providing details for each
study, in chronological order of publication, of the
location, period and controls, as well as the exposures,
cancer types and sexes studied. Eighteen were published
between 1920 and 1975 [36-52], 30 between 1976 and
1990 [53-82] and 32 between 1991 and 2007 [83-114]. In
general there was one publication per study, but Bjelke [52]
reported results from two studies, while the reference to
Gross et al. [91] is to a review, which cites results from an
unpublished study by Perry et al. Of the 80 studies, 56 were
conducted in the USA, 11 in Sweden, three in each of
Canada, Denmark and the UK, and one in each of Brazil,
Norway and Puerto Rico, with one study conducted in five
countries. Most of the studies involve only one or a small
number of cancer types, but one study [55] involves a very
wide range. The majority of the studies involve less than
1,000 cancer cases but 10 are larger than this
[38,55,56,66,70,74,89,97,99,106]. The numbers of cancers
in ST-exposed subjects are typically much lower than this,
as will become evident when the results for the individual
sites are presented. Of the different cancer sites, oral cancer
is by far the most often studied. Of the 56 US studies, 11
provide results only for chewing tobacco, five only for
snuff, and 18 only for ST, with the remaining 22 results for
more than one type. Seven of the 11 studies in Sweden
restricted attention to snuff, with three also considering
chewing and one only considering chewing.
Adjustment for smoking
ST use is not a major subject for many of the publications
from which results have been extracted. While reference is
made to ST in the title of one or more papers relating to six
of the nine cohort studies (NHANES I, CPS-I, CPS-II,
Norway Cohorts, Swedish Construction Workers and
Uppsala County), the same is true for only 15 of the 80
case-control studies. For many of the other studies
[39,42,59,61,66,70,89,91,102,104,108,109,111,113,114],
the reports only provide limited information about ST use
in the text, simply giving percentages of users in the cases
and controls or even saying there was an association or no
association, but without giving supportive data. Many
papers consider ST independently of smoking, with no
attempt to adjust ST effect estimates for smoking, even
though for many of the cancers considered smoking is
known to be a cause, and often a major cause.
To summarise the extent to which the available effect
estimates were adjusted for smoking, the studies were
divided into five groups (A = no information, B = no
adjustment, C = never smokers, D = some adjustment, E =
more adjustment) as described more fully in the methods.
Of the nine cohort studies, the numbers in the five
categories were, respectively, 0, 1, 3, 3 and 2. The Iowa
study [20] failed to take smoking into account at all, while
the CPS-I and CPS-II studies [23] and the main results from
NHANES I [22] were restricted to never smokers. In the
remaining five cohort studies, the extent of smoking
adjustment varied from publication to publication, but
amount smoked or duration of smoking were never taken
into account in the US Veterans, Norway cohorts and
Uppsala County studies so they are classified as group D.
In the Lutheran Brotherhood study, amount smoked was
taken into account in the analyses of pancreatic cancer [13]
and stomach cancer [12], and in the Swedish Construction
Workers study, amount smoked was adjusted for in the
analyses of stomach and oesophageal cancer [34], and
cutaneous squamous cell carcinoma [29], and they are
therefore classified as group E.
Of the 80 case-control studies considered, details of the
adjustment factors used are not provided in either of the
studies reported by Bjelke [52] or in two other studies
[93,109] (category A). For a further 38 studies
[36,38-40,42,44-46,49,51,53,54,56,57,59,60,63,64,67,-
70-73,75,78,80-82,84-86,92,95,96,98,100,103,110] the
results available for ST are for the whole population,
with no adjustment for smoking (category B). In 14
studies [43,47,48,66,69,74,76,83,87,88,99,101,111,112]
the only relevant smoking-adjusted results reported are
for never smokers (category C). In the remaining 24
studies, some smoking-adjusted results are available
for the whole population. Fourteen of these
[37,41,50,58,61,62,65,94,97,102,104,107,108,114] can
be classified into category D. In only 10 reports
[55,68,77,79,89-91,105,106,113], is some account
taken of daily dose and/or duration of smoking
(category E).
Oropharyngeal cancer
Table 3 presents individual effect estimates from six
cohort and 34 case-control studies, with 36 of the 40
studies providing estimates with CI that could be used in
meta-analyses, the other four [40,71,86,92] finding no
significant relationship. Thirty-eight of the 41 estimates
included in the first meta-analysis (see Table 4) are those
given in our earlier review of ST and oral cancer [4], three
recently published studies [32,35,113] being introduced
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association with any ST use (1.79, 1.36–2.36) that,
though highly significant, is based on an extremely
heterogeneous set of estimates (P < 0.001). Limiting
consideration to smoking-adjusted data, the estimate
reduces substantially, to 1.36 (1.04–1.77, n =1 9 ) ,
though it is still significant, and marked heterogeneity
remains (P < 0.001). Further limiting attention to
estimates adjusted for both smoking and alcohol, the
two major risk factors for oropharyngeal cancer [7,8],
eliminates both heterogeneity and excess risk (1.07,
0.84–1.37, n = 10). A significant relationship is seen in
never smokers (1.72, 1.01–2.94, n = 9), though the
estimates are heterogeneous (P = 0.044), and generally
based on a very small number of oropharyngeal cancer
cases that used ST.
Table 4: Oropharyngeal cancer; meta-analysis results
Heterogeneity
Type of ST
(region)
a
Adjustments/
restrictions
b
Number of estimates (RR/OR ids)
c Random-effects
RR/OR (95% CI)
c
2 I
2 P(c
2)
Any Overall data n = 41 (1, 2, 3, 6, 7, 11, 15, 16, 18, 19, 20, 21, 22,
23, 24,
25, 26, 28, 29, 30, 33, 34, 35, 38, 39, 41, 42, 46,
47, 48, 49, 51,
55, 56, 58, 60, 63, 65, 73, 74, 77)
1.79 (1.36–2.36) 335.6 88.1 < 0.001
Smoking-adjusted n = 19 (2, 3, 6, 7, 11, 13, 18, 26, 35, 43, 48, 51, 55,
56, 58, 63, 69, 74, 77)
1.36 (1.04–1.77) 69.5 74.1 < 0.001
Smoking and
alcohol adjusted
n = 10 (2, 3, 11, 51, 55, 56, 63, 69, 74, 77) 1.07 (0.84–1.37) 12.5 28.0 0.186
Never smokers n = 9 (2, 3, 10, 12, 27, 43, 48, 59, 72) 1.72 (1.01–2.94) 15.9 49.7 0.044
Never smokers
– alcohol adjusted
n = 3 (2, 3, 12) 1.87 (0.82–4.27) 0.6 0.0 0.731
Any (USA)
d Overall data n = 31 (1, 2, 3, 15, 16, 18, 19, 20, 21, 22, 23, 24,
25, 26, 29, 30,
33, 34, 35, 38, 39, 41, 42, 46, 49, 51, 55, 56, 58,
65, 74)
2.16 (1.55–3.02) 275.8 89.1 < 0.001
Smoking-adjusted n = 12 (2, 3, 13, 18, 26, 35, 43, 51, 55, 56, 58, 74) 1.65 (1.22–2.25) 33.6 67.3 < 0.001
Smoking and
alcohol adjusted
n = 6 (2, 3, 51, 55, 56, 74) 1.04 (0.80–1.35) 1.8 0.0 0.875
Never smokers n = 5 (2, 3, 27, 43, 59) 3.33 (1.76–6.32) 3.5 0.0 0.476
Never smokers –
alcohol adjusted
n = 2 (2, 3) 1.58 (0.52–4.81) 0.4 0.0 0.512
Snuff
(Scandinavia)
Overall data n = 7 (6, 7, 11, 48, 63, 69, 77) 0.97 (0.68–1.37) 14.5 58.8 0.024
Smoking-adjusted n = 7 (6, 7, 11, 48, 63, 69, 77) 0.97 (0.68–1.37) 14.5 58.8 0.024
Smoking and
alcohol adjusted
n = 4 (11, 63, 69, 77) 1.10 (0.64–1.90) 10.7 71.9 0.014
Never smokers n = 4 (10, 12, 48, 72) 1.01 (0.71–1.45) 2.2 0.0 0.524
Never smokers –
alcohol adjusted
n = 1 (12) 2.30 (0.67–7.92) –– –
Published since
1990
Overall data n = 18 (1, 2, 3, 6, 7, 11, 48, 49, 51, 55, 56, 58, 60,
63, 65, 73, 74, 77)
1.28 (0.94–1.76) 81.7 79.2 < 0.001
Smoking-adjusted n = 14 (2, 3, 6, 7, 11, 48, 51, 55, 56, 58, 63, 69, 74,
77)
1.00 (0.83–1.20) 18.5 29.8 0.139
Smoking and
alcohol adjusted
n = 10 (2, 3, 11, 51, 55, 56, 63, 69, 74, 77) 1.07 (0.84–1.37) 12.5 28.0 0.186
Never smokers n = 7 (2, 3, 10, 12, 48, 59, 72) 1.24 (0.80–1.90) 7.5 20.1 0.277
Never smokers –
alcohol adjusted
n = 3 (2, 3, 12) 1.87 (0.82–4.27) 0.6 0.0 0.731
aFor each study/sex, the RR/OR for ST from Table 3 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 3.
dIncludes estimates 24 and 25 from a study in Puerto Rico [49].
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
BMC Medicine 2009, 7:36 http://www.biomedcentral.com/1741-7015/7/36
Page 12 of 47
(page number not for citation purposes)When the analyses are restricted to US studies, the
pattern is similar to that for the overall data, with the
effect estimates reduced when attention is limited to
those that are smoking-adjusted, and close to 1.0 when
estimates that are adjusted both for smoking and alcohol
are considered. The effect estimate for never smokers is
significantly increased (3.33, 1.76–6.32), based on five
small studies, in total involving 19 ST-exposed orophar-
yngeal cancer cases.
No real evidence of a relationship with snuff use is seen
in studies conducted in Scandinavia, where seven
estimates, all adjusted for smoking, and four addition-
ally adjusted for alcohol, give a combined estimate of
0.97 (0.68–1.37). However some heterogeneity should
be noted, a high RR of 3.1 (1.5–6.6) in the Uppsala
County study [35] conflicting with six other estimates
ranging from 0.67 to 1.10.
Many of the higher estimates seen in Table 4 come from
older studies which often did not adjust for smoking. If
attention is limited to studies published since 1990,
which generally did adjust, no association is seen.
Indeed, the combined estimate from the 14 smoking-
adjusted studies published since 1990 is 1.00 (0.83–
1.20), and shows no significant heterogeneity.
While the choice of 1990 as the cut-point was not defined a
priori, the change in estimates about that time is very clear.
As shown in Figure 2, smoking-adjusted estimates for case-
control studies published between 1920 and 1988 are
consistently high (overall 2.38, 95% CI 1.87–3.04), while
estimates for case-control studies published between 1991
and 2005 show no association at all (0.98, 0.83–1.16).
There is no evidence of heterogeneity within either period
(P =0 . 3 4f o rp r e - 1 9 9 0a n dP = 0.93 for post-1990) and a
highly significant (P < 0.001) difference between estimates
in the two periods. Smoking-adjusted estimates for the
cohort studies which, though published between 2005 and
2008, generally cover a long follow-up period extending
from before 1990, give an intermediate result (1.32, 0.65–
2.68).
The findings are very similar to those in an earlier review
[4]. That review provides additional meta-analyses of the
slightly smaller data set, further investigating variation
by type of ST, sex, study design, study location and study
period. It also provides full det a i l so ft h ev a r i o u st y p e so f
cancer that have been considered in the source papers.
The evidence presented suggests that snuff as used in
Scandinavia has no effect on oropharyngeal cancer risk.
Products used in the past in the USA may have increased
the risk but any effect that exists now seems likely to be
quite small.
Oesophageal cancer
Table 5 summarises the data from four cohort and 10 case-
controlstudies.Forfiveofthesestudieseffectestimateswith
CIarenotavailable,oneofthese[52]reportinga‘synergistic
effect of tobacco chewing and alcohol’, another [19]
presenting a RR of 2.28, but not whether it was significant,
and the others [14,40,60] showing no significant relation-
ship. Of the remaining nine studies, six provide smoking-
adjusted estimates, three of which are also adjusted for
alcohol. Though estimates are generally somewhat above
1.0 in these nine studies, they are rarely significant,
exceptions being the estimate of 1.92 (1.00–3.68) for
snuffinneversmokersintheSwedishConstructionWorkers
study [34] and that for chewing of 2.39 (1.23–4.64) in the
Wynder and Bross case-control study [44].
The meta-analyses (see Table 6 and Figure 3) show some
indication of an association, though this is not always
statistically significant. Based on all available smoking-
adjusted data, the combined estimate for any ST use is 1.13
(0.95–1.36, n = 7), somewhat lower than when there is no
restriction to smoking-adjusted data (1.25, 1.03–1.51, n =
10). The corresponding analyses show no real indication of
an effect for snuff in Scandinavia, but are more suggestive
for the USA. Even here, the smoking-adjusted estimate is
not significant (1.89, 0.84–4.25), though this is based on
only three small studies, involving a total of 11 cases using
ST. The estimates based on all the available smoking-
adjusted data include an any smoking RR of 1.00 (0.79–
1.27) from the study with the largest weight, the Swedish
Construction Workers study [34], this RR being derived by
combining the findings for adenocarcinoma and squa-
mous cell carcinoma. The meta-analyses for never smokers
give a higher combined estimate of 1.91 (1.15–3.17, n =4 )
for any ST use, mainly because they use a higher
(combined adeno/squamous) estimate of 1.92 (1.00–
3.68) for the Swedish Construction Workers study [34].
Overall, the data must be regarded as providing
suggestive evidence of a possible weak relationship
between ST use and oesophageal cancer.
Stomach cancer
Table 7 presents results from 12 studies, eight of which
provide a total of 17 estimates which could be used in
meta-analyses. Although the Swedish construction work-
ers study [34] shows a significant increase in risk of
stomach cancer associated with snuff use for never
smokers (RR 1.33, 95% CI 1.03–1.72), no other
significant associations are reported, and the meta-
analyses conducted (see Table 8 and Figure 4) are all
non-significant. Based on smoking-adjusted estimates
from eight studies, the combined RR estimate is 1.03
(95% CI 0.88–1.20). Four studies did not provide
BMC Medicine 2009, 7:36 http://www.biomedcentral.com/1741-7015/7/36
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Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
PROSPECTIVE
  2 M CPS-I 2.02 (0.53, 7.74)
  3 M CPS-II 0.90 (0.12, 6.71)
  6 M Norway Cohorts 1.10 (0.50, 2.41)
  7 M Swedish construction workers 0.70 (0.50, 0.90)
  11 M Uppsala County 3.10 (1.50, 6.60)
Subtotal (95% CI) 1.32 (0.65, 2.68)
CASE CONTROL BEFORE 1990
  13 M+F Broders 1920 2.05 (1.48, 2.83)
  18 M Wynder and Bross 1957 2.00 (1.16, 3.47)
  26 M Keller 1970 3.63 (1.02, 12.95)
  35 F Winn et al 1981 2.67 (1.83, 3.90)
  43 F Blot et al 1988 6.20 (1.90, 19.80)
Subtotal (95% CI) 2.38 (1.87, 3.04)
CASE CONTROL 1990 OR LATER
  48 M+F Blomqvist et al 1991 0.67 (0.08, 5.75)
  51 M+F Sterling et al 1992 1.04 (0.41, 2.68)
  55 M Mashberg et al 1993 0.96 (0.70, 1.33)
  56 M+F Perry et al 1993 1.43 (0.64, 3.21)
  58 M Kabat et al 1994 1.11 (0.81, 1.53)
  63 M Lewin et al 1998 0.98 (0.63, 1.50)
  69 M+F Schildt et al 1998 0.80 (0.50, 1.30)
  74 M Schwartz et al 1998 1.00 (0.40, 2.30)
  77 M+F Rosenquist et al 2005 0.70 (0.30, 1.30)
Subtotal (95% CI) 0.98 (0.83, 1.16)
Total (95% CI) 1.36 (1.04, 1.77)
Figure 2
Smokeless tobacco and oropharyngeal cancer by study type and period of publication (smoking-adjusted data).
The 19 individual smoking-adjusted relative risk (RR) and 95% confidence interval (CI) estimates separated by study type, and
for case-control studies by period of publication, are shown numerically and also graphically on a logarithmic scale. They are
sorted in order of year of publication. In the graphical representation individual RR estimates are indicated by a solid square,
with the area of the square proportional to the weight (inverse-variance) of the estimate. Also shown are the combined
estimates, for the subgroups and overall, derived by random-effects meta-analysis. These are represented by a diamond of
standard height, with the width indicating the 95% CI. See Table 3 for further details relating to the estimates, and Table 4
for fuller details of the meta-analyses.
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(page number not for citation purposes)detailed data. No association with stomach cancer was
reported by Weinberg et al.[ 6 7 ]o rf o rt h eU Sd a t a
considered by Bjelke [52]. However, Bjelke did report an
“Association ... with tobacco chewing” for the Norwegian
data, and a standardised mortality ratio of 1.51 was
given for the US Veterans’ Study [19], but not whether
this was statistically significant.
The combined evidence does not indicate an effect of ST
use on the risk of stomach cancer.
Pancreatic cancer
Table 9 presents results from four cohort and seven case-
control studies. For four of the studies effect estimates
that can be included in meta-analyses are not available;
two [75,84] of these studies merely reported finding no
association, one [19] reported an elevated RR of 1.65
with no CI, and another [82] a reduced RR of 0.80, also
with no CI. Of the other seven studies, significant
increases have been reported in two. The Norway cohorts
study [26] reports an increase in ever users of snuff in a
Table 5: Oesophageal cancer; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex
d Id. Cases
e Estimate (95%CI)
d Adjustment factors
f
Cohort studies
Lutheran Brotherhood: IARC Monograph
37 1985 [14]
ST Ever Any M 1 NA 2.6 (not significant) age, res
US Veterans: Winn et al. 1982 [19] ST Ever Never M
g 2 1 2.28 (NA) age
Norway cohorts: Boffetta et al. 2005 [26] Snuff Current Any M 3 4 1.06 (0.35–3.23) age, smok
Former M 4 5 1.90 (0.69–5.27)
Ever M 5 9 1.40 (0.61–3.24)
Swedish construction workers: Zendehdel
et al. 2008 [34]
Snuff Ever Any M 6 77 1.00 (0.79–1.27)
h a g e ,b m i ,s m o k
Never 7 11 1.92 (1.00–3.68)
i age, bmi
Case-control studies
Wynder et al. 1957 [40] Chew Ever Any M 8 NA no association
j none
Wynder and Bross 1961 [44] Chew Ever Any M 9 21 2.39 (1.23–4.64)
k none
Martinez et al. 1969 [49] Chew Use Never M 10 3 1.18 (0.28–4.90)
k none
F 11 7 2.69 (0.92–7.87)
k
Bjelke et al. 1974 USA [52] Chew Use NA NA 12 NA association
l NA
Williams and Horm 1977 [55] ST Ever Any M 13 2 0.55 (0.13–2.31) none
Wynder and Stellman 1977 [56] Chew Ever Any M 14 20 1.23 (0.76–1.99)
k none
Snuff 15 8 1.65 (0.78–3.49)
k
ST 16 28 1.35 (0.89–2.06)
m
Pottern et al. 1981 [60] Chew Ever Any M 17 4 no association
n none
Snuff 18 2 no association
n
Morris Brown et al. 1988 [76] ST Ever Never M 19 1 1.20 (0.10–13.30) alc, incm
Lewin et al. 1998 [102] Snuff Current Any M 20 10 1.10 (0.50–2.40) age, alc, res, smok
Former 21 9 1.30 (0.60–3.10)
Ever 22 19 1.20 (0.70–2.20)
Lagergren et al. 2000 [108] Snuff Ever Any M+F 23 68 1.31 (0.89–1.92)
k age, alc, bmi, diet,
edu, exer, rflx, sex,
smok
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non-use.
dNA = not available.
e'Id.' is the RR/OR identification number used in Table 6, and 'Cases' is the number of cases in ST users as defined. NA = not available.
fAbbreviations used: alc = alcohol, bmi = body mass index, edu = education, exer = exercise, incm = incidence or mortality, res = area of residence,
rflx = reflux symptoms, smok = smoking, NA = not available.
gThe population included < 0.5% females.
hRRs for adenocarcinoma (1.0, 95% CI 0.6–1.5) and squamous cell carcinoma (1.0, 0.8–1.4) combined.
iRRs for adenocarcinoma (0.2, 95% CI 0.0–1.9) and squamous cell carcinoma (3.5, 1.6–7.6) combined.
jThe average ridit duration of chewing was non-significantly lower in the oesophageal cancer cases.
kRR/OR and/or 95% CI estimated from data provided in the source.
lThe abstract noted a "synergistic effect of tobacco chewing and alcohol".
mRR/OR and/or 95% CI estimated from data provided in the source assuming that no one both chewed and used snuff.
nThe authors noted the percentage of ever users was "slightly higher" in the controls than in the cases for chewing but not for snuff.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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(page number not for citation purposes)Table 6: Oesophageal cancer; meta-analysis results
Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any Overall data 10 (5, 6, 9, 10, 11, 13, 16, 19, 22, 23) 1.25 (1.03–1.51) 10.3 13.0 0.324
Smoking-adjusted 7 (5, 6, 10, 11, 19, 22, 23) 1.13 (0.95–1.36) 4.4 0.0 0.623
Never smokers 4 (7, 10, 11, 19) 1.91 (1.15–3.17) 1.0 0.0 0.810
Any (USA)
d Overall data 6 (9, 10, 11, 13, 16, 19) 1.56 (1.11–2.19) 5.2 4.6 0.387
Smoking-adjusted 3 (10, 11, 19) 1.89 (0.84–4.25) 1.0 0.0 0.617
Never smokers 3 (10, 11, 19) 1.89 (0.84–4.25) 1.0 0.0 0.617
Snuff (Scandinavia) Overall data 4 (5, 6, 22, 23) 1.10 (0.92–1.33) 1.8 0.0 0.61
Smoking-adjusted 4 (5, 6, 22, 23) 1.10 (0.92–1.33) 1.8 0.0 0.61
Never smokers 1 (7) 1.92 (1.00–3.68) –– –
aFor each study/sex, the RR/OR for ST from Table 5 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 5.
dIncludes estimates 10 and 11 from a study in Puerto Rico [49]
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
USA
  10 M Martinez et al 1969 1.18 (0.28, 4.90)
  11 F Martinez et al 1969 2.69 (0.92, 7.87)
  19 M Morris Brown et al 1988 1.20 (0.10, 13.30)
Subtotal (95% CI) 1.89 (0.84, 4.25)
SCANDINAVIA
  5 M Norway cohorts 1.40 (0.61, 3.24)
  6 M Swedish construction workers 1.00 (0.79, 1.27)
  22 M Lewin et al 1998 1.20 (0.70, 2.20)
  23 M+F Lagergren et al 2000 1.31 (0.89, 1.92)
Subtotal (95% CI) 1.10 (0.92, 1.33)
Total (95% CI) 1.13 (0.95, 1.36)
Figure 3
Smokeless tobacco and oesophageal cancer by region (smoking-adjusted data). The seven individual smoking-
adjusted relative risk (RR) and 95% confidence interval (CI) estimates, separated by region, are shown numerically and also
graphically on a logarithmic scale. They are sorted in order of year of publication within study type (cohort, case-control). In
the graphical representation individual RR estimates are indicated by a solid square, with the area of the square proportional to
the weight (inverse-variance) of the estimate. Also shown are the combined estimates, for the subgroups and overall, derived
by random-effects meta-analysis. These are represented by a diamond of standard height, with the width indicating the
95% CI. See Table 5 for further details relating to the estimates, and Table 6 for fuller details of the meta-analyses.
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tion (1.67, 95% CI 1.12–2.50) but not in an analysis
based on never smokers (0.85, 0.24–3.07). Conversely,
the Swedish construction workers study shows no
increase in a smoking-adjusted analysis based on the
whole population (0.9, 0.7–1.2), but an increase in
never smokers (2.0, 1.2–3 . 3 ) .N o n eo ft h et h r e em e t a -
analyses presented in Table 10 (see also Figure 5) for any
ST use show any significant increase, though they all
show evidence of heterogeneity. Smoking-adjusted over-
all population effect estimates are available for all seven
studies considered, the combined estimate being 1.07
(0.71–1.60). For never smokers, the estimate is 1.23
(0.66–2.31, n = 5). No significant associations are seen
in the separate meta-analyses for the USA and Scandi-
navia.
At most, the overall data weakly suggest a possible effect
of ST on pancreatic cancer risk. A fuller discussion of
these data is available elsewhere [5].
Other cancers of the digestive system
Table 11 summarises evidence relating to cancers of the
digestive system other than those considered already in
Tables 5, 7 and 9. Nine studies are considered, four
Table 7: Stomach cancer; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex
d Id. Cases
e Estimate (95%CI)
d Adjustment factors
f
Cohort studies
Lutheran Brotherhood: Kneller et al.
1991 [12]
ST Ever Any M 1 18 1.60 (0.58–4.50) age, byr, smok
Never M 2 3 3.80 (1.00–14.32) age, byr
US Veterans: Winn et al. 1982 [19] ST Ever Never M
g 3 NA 1.51 (NA) age
CPS-II: Chao et al. 2002 [24] ST Current Never M 4 8 1.58 (0.76–3.28) age, asp, diet, edu, fhis, race, vit
Former 5 2 1.11 (0.27–4.50)
Ever 6 10 1.45 (0.75–2.80)
h
Norway cohorts: Boffetta et al. 2005
[26]
Snuff Current Any M 7 42 1.00 (0.71–1.42) age, smok
Former 8 32 1.29 (0.87–1.91)
Ever 9 74 1.11 (0.83–1.48)
Swedish construction workers:
Zendehdel et al. 2008 [34]
Snuff Ever Any M 10 311 1.08 (0.96–1.22)
i a g e ,b m i ,s m o k
Ever Never M 11 76 1.33 (1.03–1.72)
j age, bmi
Case-control studies
Bjelke 1974 (USA) [52] Chew Use Any NA 12 NA no association NA
Bjelke 1974 (Norway) [52] Chew Use Any NA 13 NA association NA
Williams and Horm 1977 [55] ST Ever Any M 14 12 1.31 (0.71–2.43)
h age, race, smok
F 15 2 1.50 (0.36–6.26) none
Weinberg et al. 1985 [67] Chew Ever Any M 16 NA no association none
Hansson et al. 1994 [94] Snuff Use Any M+F 17 NA 0.70 (0.47–1.06) age, ses, sex, smok
Ye et al. 1999 [107] Chew Ever Any M+F 18 8 1.30 (0.54–3.12)
h none
Snuff Ever M 19 83 0.77 (0.56–1.06)
h a g e ,a l c ,b m i ,r e s ,s e s ,s m o k
Never M 20 11 0.50 (0.20–1.20) age, alc, bmi, res, ses
Lagergren et al. 2000 [108] Snuff Ever Any M+F 21 53 1.20 (0.80–1.80) age, alc, bmi, diet, edu, exer,
r f l x ,s e x ,s m o k
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
dNA = not available.
e'Id.' is the RR/OR identification number used in Table 8, and 'Cases' is the number of cases in ST users as defined. NA = not available.
fAbbreviations used: alc = alcohol, asp = aspirin, bmi = body mass index, byr = birth year, edu = education, exer = exercise, fhis = family history of
stomach cancer, incm = incidence or mortality, res = area of residence, rflx = reflux symptoms, ses = socioeconomic status, smok = smoking,
vit = vitamins, NA = not available.
gThe population included < 0.5% females.
hEstimated from data provided in the source.
iRRs for cardia (1.0, 95% CI 0.8–1.4) and noncardia stomach cancer (1.1, 1.0–1.3) combined.
jRRs for cardia (0.9, 95% CI 0.4–2.0) and noncardia stomach cancer (1.4, 1.1–1.9) combined.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
BMC Medicine 2009, 7:36 http://www.biomedcentral.com/1741-7015/7/36
Page 17 of 47
(page number not for citation purposes)Table 8: Stomach cancer; meta-analysis results
Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any Overall data 9 (1, 6, 9, 10, 14, 15, 17, 19, 21) 1.03 (0.90–1.19) 10.5 24.0 0.230
Smoking-adjusted 8 (1, 6, 9, 10, 14, 17, 19, 21) 1.03 (0.88–1.20) 10.3 31.9 0.173
Never smokers 4 (2, 6, 11, 20) 1.27 (0.75–2.13) 7.0 57.2 0.072
Any (USA) Overall data 4 (1, 6, 14, 15) 1.41 (0.95–2.10) 0.1 0.0 0.988
Smoking-adjusted 3 (1, 6, 14) 1.41 (0.93–2.12) 0.1 0.0 0.942
Never smokers 2 (2, 6) 1.96 (0.82–4.70) 1.6 38.2 0.203
Snuff (Scandinavia) Overall data 5 (9, 10, 17, 19, 21) 0.98 (0.82–1.17) 8.1 50.4 0.089
Smoking-adjusted 5 (9, 10, 17, 19, 21) 0.98 (0.82–1.17) 8.1 50.4 0.089
Never smokers 2 (11, 20) 0.90 (0.35–2.30) 4.2 76.4 0.040
aFor each study/sex, the RR/OR for ST from Table 7 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 7.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
USA
  1 M Lutheran Brotherhood 1.60 (0.58, 4.50)
  6 M CPS-II 1.45 (0.75, 2.80)
  14 M Williams and Horm 1977 1.31 (0.71, 2.43)
Subtotal (95% CI) 1.41 (0.93, 2.12)
SCANDINAVIA
  9 M Norway Cohorts 1.11 (0.83, 1.48)
  10 M Swedish construction workers 1.08 (0.96, 1.22)
  17 M+F Hansson et al 1994 0.70 (0.47, 1.06)
  19 M Ye et al 1999 0.77 (0.56, 1.06)
  21 M+F Lagergren et al 2000 1.20 (0.80, 1.80)
Subtotal (95% CI) 0.98 (0.82, 1.17)
Total (95% CI) 1.03 (0.88, 1.20)
Figure 4
Smokeless tobacco and stomach cancer by region (smoking-adjusted data). The eight individual smoking-adjusted
relative risk (RR) and 95% confidence interval (CI) estimates, separated by region, are shown numerically and also
graphically on a logarithmic scale. They are sorted in order of year of publication within study type (cohort, case-control).
In the graphical representation individual RR estimates are indicated by a solid square, with the area of the square proportional
to the weight (inverse-variance) of the estimate. Also shown are the combined estimates, for the subgroups and overall,
derived by random-effects meta-analysis. These are represented by a diamond of standard height, with the width indicating
the 95% CI. See Table 7 for further details relating to the estimates, and Table 8 for fuller details of the meta-analyses.
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providing data for colon cancer, rectal cancer, colorectal
cancer, small intestine cancer, liver cancer, gall bladder
and bile duct cancer. These data, which are insufficient
for meta-analysis, include two statistically significant
effect estimates: an RR of 1.9 (1.2–3.1) for rectal cancer
and ST use from the US Veterans study [18] and a
remarkably high OR from the case-control study of
Chow et al. [93] of 18.0 (1.4–227.7) for bile duct cancer
and chewing tobacco, based on only three exposed cases.
There are rather more data for the combined category of
all cancers of the digestive system. Of the four studies
providing data, all conducted in the USA, NHANES I
Table 9: Pancreatic cancer; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI)
e Adjustment factors
f
Cohort studies
Lutheran Brotherhood: Zheng et al. 1993
[13]
ST Ever Any M 1 16 1.70 (0.90–3.10) age, alc, smok
US Veterans: Winn et al. 1982 [19] ST Ever Never M
g 2 NA 1.65 (NA) age
Norway cohorts: Boffetta et al. 2005 [26] Snuff Current Any M 3 27 1.60 (1.00–2.55) age, smok
Former 4 18 1.80 (1.04–3.09)
Ever 5 45 1.67 (1.12–2.50)
Ever Never 6 3 0.85 (0.24–3.07) age
Swedish construction workers: Luo et al.
2007 [32]
Snuff Ever Any M 7 NA 0.90 (0.70–1.20) age, bmi, smok
Current Never 8 18 2.10 (1.20–3.60) age, bmi
Former 9 2 1.40 (0.40–5.90)
Ever 10 20 2.00 (1.20–3.30)
Case-control studies
Williams and Horm 1977[55] ST Ever Any M 11 3 0.29 (0.09–0.92)
h age, race, smok
Falk et al. 1988 [75] Chew Use Any M+F 12 NA no association none
Snuff 13 NA no association
Farrow and Davis 1990 [82] Chew Ever Any M 14 NA 0.80 (NA) edu, race
Ghadirian et al. 1991[84] Chew Use Any M+F 15 NA no association none
Muscat et al. 1997 [101] Chew Ever Never
i M 16 6 2.82 (0.85–9.39)
j none
Snuff Any 17 2 1.32 (0.22–7.93)
Alguacil and Silverman 2004 [111] ST Ever Never
k M+F 18 5 1.10 (0.40–3.10) age, race, res, sex, smok
k
Hassan et al. 2007 [114] Chew Ever Any M+F 19 34 0.70 (0.40–1.10) age, alc, diab, edu, mar,
r a c e ,r e s ,s e x ,s m o k
Never 20 10 0.60 (0.30–1.40) age, alc, diab, edu, mar,
r a c e ,r e s ,s e x
Snuff Ever Any 21 18 0.60 (0.30–1.10) age, alc, diab, edu, mar,
r a c e ,r e s ,s e x ,s m o k
Never 22 4 0.50 (0.10–1.50) age, alc, diab, edu, mar,
r a c e ,r e s ,s e x
ST Ever Any 23 52 0.65 (0.43–0.97)
l age, alc, diab, edu, mar,
r a c e ,r e s ,s e x ,s m o k
Never 24 14 0.57 (0.29–1.11)
l age, alc, diab, edu, mar,
r a c e ,r e s ,s e x
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 10, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eNA = not available.
fAbbreviations used: alc = alcohol consumption, bmi = body mass index, diab = diabetes, edu = education, mar = marital status, res = area of
residence, smok = smoking.
gThe population included < 0.5% females.
hRR/OR and/or 95% CI estimated from data provided in the source.
iIncludes long-term (10+ years) quitters.
jPersonal communication from Dr Muscat. The estimate given in the source of 3.60 (1.00–12.80) is for noncurrent smokers.
kEstimates are for never cigarette smokers with adjustment for other tobacco use.
lRR/OR and/or 95% CI estimated from data provided in the source assuming that no one both chewed and used snuff.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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(page number not for citation purposes)Table 10: Pancreatic cancer; meta-analysis results
Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any Overall data 7 (1, 5, 7, 11, 17, 18, 23) 1.00 (0.68–1.47) 18.5 67.5 0.005
Smoking-adjusted 7 (1, 5, 7, 11, 16, 18, 23) 1.07 (0.71–1.60) 21.2 71.7 0.002
Never smokers 5 (6, 10, 16, 18, 24) 1.23 (0.66–2.31) 10.7 62.7 0.030
Any (USA) Overall data 5 (1, 11, 17, 18, 23) 0.86 (0.47–1.57) 10.2 61.0 0.037
Smoking-adjusted 5 (1, 11, 16, 18, 23) 0.99 (0.51–1.91) 13.8 71.0 0.008
Never smokers 3 (16, 18, 24) 1.09 (0.44–2.67) 5.4 63.0 0.067
Snuff (Scandinavia) Overall data 2 (5, 7) 1.20 (0.66–2.20) 6.3 84.1 0.012
Smoking-adjusted 2 (5, 7) 1.20 (0.66–2.20) 6.3 84.1 0.012
Never smokers 2 (6, 10) 1.61 (0.77–3.34) 1.5 33.2 0.221
aFor each study/sex, the RR/OR for ST from Table 9 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 9.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name RelativeRis Relative Risk k
95% CI 95% CI
USA
  1 M Lutheran Brotherhood 1.70 (0.90, 3.10)
  11 M Williams and Horm 1977 0.29 (0.09, 0.92)
  16 M Muscat et al 1997 2.82 (0.85, 9.39)
  18 M+F Alguacil and Silverman 2004 1.10 (0.40, 3.10)
  23 M+F Hassan et al 2007 0.65 (0.43, 0.97)
Subtotal (95% CI) 0.99 (0.51, 1.91)
SCANDINAVIA
  5 M Norway Cohorts 1.67 (1.12, 2.50)
  7 M Swedish construction workers 0.90 (0.70, 1.20)
Subtotal (95% CI) 1.20 (0.66, 2.20)
Total (95% CI) 1.07 (0.71, 1.60)
Figure 5
Smokeless tobacco and pancreatic cancer by region (smoking-adjusted data). The seven individual smoking-
adjusted relative risk (RR) and 95% confidence interval (CI) estimates, separated by region, are shown numerically and also
graphically on a logarithmic scale. They are sorted in order of year of publication within study type (cohort, case-control). In
the graphical representation individual RR estimates are indicated by a solid square, with the area of the square proportional to
the weight (inverse-variance) of the estimate. Also shown are the combined estimates, for the subgroups and overall, derived
by random-effects meta-analysis. These are represented by a diamond of standard height, with the width indicating the 95% CI.
See Table 9 for further details relating to the estimates, and Table 10 for fuller details of the meta-analyses.
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(page number not for citation purposes)[22] and CPS-II [23] show no relationship, CPS-I [23]
a weak, but significant, positive relationship, and the
case-control study of Sterling et al. [89] a significant
negative relationship. Overall, the combined estimate
(see Table 12 and Figure 6), all based on smoking-
adjusted data, is 0.86 (0.59–1.25, n =5 ) ,w i t hs i g n i f i c a n t
evidence of heterogeneity (P = 0.002). The analysis
for never smokers removes the case-control study
and eliminates the heterogeneity. However the com-
bined estimate of 1.14 (0.99–1.33, n = 4) remains non-
significant.
More data are needed before any conclusion can be
drawn for these cancers.
Table 11: Other cancers of the digestive system; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex
d Id. Cases
e Estimate (95%CI)
d Adjustment factors
f
Cohort studies
US Veterans: Heineman et al. 1995 [18]
- colon cancer ST Ever Never M
g 1 39 1.20 (0.90–1.70)
h a g e ,s e d ,s e s ,t i m e ,
yriv
- rectal cancer Never 2 17 1.90 (1.20–3.10)
h
US Veterans: Winn et al. 1982 [19]
- liver cancer ST Ever Never M
g 3 NA 2.81 (NA) age
NHANES I: Accortt et al. 2005 [22]
- digestive cancer ST Ever Never M 4 13 0.80 (0.40–1.80) age, pov, race
F 5 4 0.80 (0.30–2.40)
CPS-I: Henley et al. 2005 [23]
- digestive cancer ST Current Never M 6 153 1.26 (1.05–1.52) age, alc, asp, bmi,
diet, edu, exer, occ,
race
CPS-II: Henley et al. 2005 [23]
- digestive cancer ST Current Never M 7 48 1.04 (0.77–1.38) age, alc, asp, bmi,
diet, edu, exer, occ,
race
Former 8 19 0.99 (0.63–1.57)
Ever 9 67 1.03 (0.80–1.31)
h
Case-control studies
Bjelke 1974 [52] USA
- colorectal cancer Chew Use Any NA 10 NA No association NA
Bjelke 1974 [52] Norway
- colorectal cancer Chew Use Any NA 11 NA No association NA
Williams and Horm 1977 [55]
- small intestine cancer ST Ever Any M 12 2 3.11 (0.65–14.8)
h age, race, smok
- colon cancer ST Ever Any M 13 30 1.36 (0.90–2.07)
h age, race, smok
F 14 7 1.28 (0.58–2.87)
h
- rectal cancer ST Ever Any M 15 13 0.75 (0.42–1.35)
h age, race, smok
F 16 2 0.87 (0.21–3.62)
h
- liver cancer ST Ever Any M 17 1 0.58 (0.08–4.39)
h none
- gall bladder cancer ST Ever Any M 18 1 0.41 (0.05–3.04)
h none
Sterling et al. 1992 [89]
- digestive cancer ST Ever Any M+F 19 555 0.40 (0.24–0.69)
h age, alc, occ, race,
sex, smok
Chow et al. 1994 [93]
- bile duct cancer
i Chew Use Any M 20 3 18.0 (1.40–227.70) NA
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
dNA = not available.
e'Id.' is the RR/OR identification number used in Table 12, and 'Cases' is the number of cases in ST users as defined. NA = not available.
fAbbreviations used: alc = alcohol, asp = aspirin, bmi = body mass index, edu = education, exer = exercise, occ = occupation, pov = poverty,
sed = sedentary lifestyle, ses = socioeconomic status, smok = smoking, yriv = year of interview, NA = not available.
gThe population included < 0.5% females.
hRR/OR and/or 95% CI estimated from data provided in the source.
iResults are for cancer of ampulla of Vater; extrahepatic bile duct cancers were also studied, but results were not given for chewing.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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The data shown in Table 13 are quite limited. The evidence
for nasal cancer is based on only three studies, none
reporting a significant association with ST use. Seven
studies investigated the relationship of ST to larynx cancer,
two providing no effect estimates and merely reporting a
lack of association. Control for confounding variables is
very limited, with only two studies providing estimates
adjusted for smoking, only one adjusting for alcohol and
no study presenting any results for never smokers. The only
study to adjust for smoking and alcohol [102], which
shows no relationship of snuff to risk of larynx cancer, is
the only study conducted in Scandinavia. Two US studies
[55,56] report a significant relationship, however, and, as
shown in Table 14 (see also Figure 7), an association is
seen in the overall data (1.43, 1.08–1.89, n =5 ) .
Given the independent role of smoking and alcohol in
larynx cancer [7,8], and the lack of association in the one
study that has adjusted for both these factors [102], any
independent association of ST use with larynx cancer risk
has not been established. More data are needed before
any conclusion can be drawn on the role of ST in larynx
and nasal cancers.
Table 12: Overall digestive cancer; meta-analysis results
Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any (USA)
d O v e r a l ld a t a 5( 4 ,5 ,6 ,9 ,1 9 ) 0 . 8 6( 0 . 5 9 –1.25) 17.3 76.9 0.002
Smoking-adjusted 5 (4, 5, 6, 9, 19) 0.86 (0.59–1.25) 17.3 76.9 0.002
Never smokers 4 (4, 5, 6, 9) 1.14 (0.99–1.33) 3.1 2.1 0.382
aFor each study/sex, the RR/OR for ST from Table 11 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 11.
dAll the available data for overall digestive cancer are from US studies.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
  4 M NHANES I 0.80 (0.40, 1.80)
  5 F NHANES I 0.80 (0.30, 2.40)
  6 M CPS-I 1.26 (1.05, 1.52)
  9 M CPS-II 1.03 (0.80, 1.31)
  19 M+F Sterling et al 1992 0.40 (0.24, 0.69)
Total (95% CI) 0.86 (0.59, 1.25)
Figure 6
Smokeless tobacco and overall digestive cancer (USA smoking-adjusted data). The five individual relative risk (RR)
and 95% confidence interval (CI) estimates, all smoking-adjusted and for the USA, are shown numerically and also graphically
on a logarithmic scale. They are sorted in order of year of publication within study type (cohort, case-control). In the graphical
representation individual RR estimates are indicated by a solid square, with the area of the square proportional to the weight
(inverse-variance) of the estimate. Also shown is the combined estimate, derived by random-effects meta-analysis. This is
represented by a diamond of standard height, with the width indicating the 95% CI. See Table 11 for further details relating to
the estimates, and Table 12 for fuller details of the meta-analysis.
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Table 15 summarises data from six cohort and three case-
control studies. The case-control studies provide only
estimates for smokers and non-smokers combined, and
only one of these is adjusted for smoking. The cohort
studies all provide estimates for never smokers, with
two also giving smoking-adjusted results for the overall
population. The meta-analyses (see Table 16 and Figure 8)
show no evidence that ST use increases risk of lung cancer,
with the combined estimate for smoking-adjusted data
0.99 (95% CI 0.71–1.37). However, there is considerable
heterogeneity (P < 0.001), the major contributors to this
being the high RR of 6.80 (1.60–28.5) in never smokers in
NHANES I [22], the significant increase of 1.77 (1.14–
2.74) from CPS-II [23], and the low RR of 0.70 (0.60–0.70)
for the Swedish construction workers study [32]. While the
combined estimate for never smokers for any ST use is
greater than 1.0 (1.34, 0.80–2.23, n = 5), it is not statis-
tically significant.
While the data have unexplained heterogeneity, they do
not provide any clear indication of a relationship of lung
cancer to ST use.
Not included in Table 15 are results from an analysis
conducted by Henley et al.i n2 0 0 7[ 2 5 ]b a s e do nf o l l o w -
up of the CPS-II cohort from 1982 to 2002. They report
an increased risk of lung cancer (1.46, 1.24–1.73) in men
w h os w i t c h e df r o mc i g a r e t t es m o k i n gt oS Tc o m p a r e d
with those who quit entirely, after adjusting for age,
other demographic variables, as well as variables
associated with smoking history. This analysis may be
biased by reliance on tobacco use data recorded in 1982,
and by residual confounding, with the paper reporting
Table 13: Larynx and nasal cancer; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI) Adjustment factors
e
Case-control studies
Wynder et al. 1957 [40]
- larynx cancer Chew Ever Any M 1 NA no association
f none
Vincent and Marchetta 1963 [45]
- larynx cancer Snuff Use Any M 2 5 1.81 (0.33–9.97) none
Williams and Horm 1977 [55]
- larynx cancer ST Ever Any M 3 16 2.01 (1.15–3.51)
g age, race, smok
Wynder and Stellman 1977 [56]
- larynx cancer Chew Ever Any M 4 46 1.35 (0.96–1.89)
g none
Snuff 5 15 1.46 (0.82–2.57)
g none
ST 6 61 1.40 (1.04–1.89)
h none
Engzell et al. 1978 [57]
- nasal cancer Snuff Use Any M 7 NA no association none
Brinton et al. 1984 [64]
- nasal cancer Chew Use Any M+F 8 15 0.74 (0.40–1.50) sex
Snuff 9 23 1.47 (0.80–2.80)
ST 10 38 1.08 (0.68–1.70)
h none
Stockwell and Lyman 1986 [70]
- nasal cancer ST Ever Any M+F 11 1 2.93 (0.40–21.66)
g none
- larynx cancer ST Ever Any M+F 12 6 2.02 (0.84–4.86)
g none
Young et al. 1986 [71]
- larynx cancer ST Ever Any M 13 NA no association none
Lewin et al. 1998 [102]
- larynx cancer Snuff Current Any M 14 15 1.00 (0.50–1.90) age, alc, res, smok
Former 15 9 0.80 (0.40–1.70)
Ever 16 24 0.90 (0.50–1.50)
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 14, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eAbbreviations used: alc = alcohol, res = area of residence, smok = smoking.
fThe average ridit duration of chewing was non-significantly lower in the larynx cancer cases.
gRR/OR and/or 95% CI estimated from data provided in the source.
hRR/OR and/or 95% CI estimated from data provided in the source assuming that no one both chewed and used snuff.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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(page number not for citation purposes)Table 14: Larynx and nasal cancer; meta-analysis results
Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Larynx cancer
d
Any Overall data 5 (2, 3, 6, 12, 16) 1.43 (1.08–1.89) 4.8 17.4 0.304
Smoking-adjusted 2 (3, 16) 1.34 (0.61–2.95) 4.0 75.3 0.044
Any (USA) Overall data 4 (2, 3, 6, 12) 1.56 (1.21–2.00) 1.7 0.0 0.646
Smoking-adjusted 1 (3) 2.01 (1.15–3.51) –– –
Snuff (Scandinavia) Overall data 1 (16) 0.90 (0.50–1.50) –– –
Smoking-adjusted 1 (16) 0.90 (0.50–1.50) –– –
Nasal cancer
e
Any Overall data 2 (10, 11) 1.14 (0.73–1.77) 0.9 0.0 0.339
aFor each study/sex, the RR/OR for ST from Table 13 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 13.
dFor larynx cancer there are no data for never smokers.
eFor nasal cancer the only data are from US studies and not smoking-adjusted.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
USA
  2 M Vincent and Marchetta 1963 1.81 (0.33, 9.97)
  3 M Williams and Horm 1977 2.01 (1.15, 3.51)
  6 M Wynder and Stellman 1977 1.40 (1.04, 1.89)
  12 M+F Stockwell and Lyman 1986 2.02 (0.84, 4.86)
Subtotal (95% CI) 1.56 (1.21, 2.00)
SCANDINAVIA
  16 M Lewin et al 1998 0.90 (0.50, 1.50)
Subtotal (95% CI) 0.90 (0.52, 1.56)
Total (95% CI) 1.43 (1.08, 1.89)
Figure 7
Smokeless tobacco and larynx cancer by region (overall data). The five individual relative risk (RR) and 95%
confidence interval (CI) estimates, separated by region, are shown numerically and also graphically on a logarithmic scale. They
are sorted in order of year of publication within study type (cohort, case-control). In the graphical representation individual
RR estimates are indicated by a solid square, with the area of the square proportional to the weight (inverse-variance) of the
estimate. Also shown are the combined estimates, for the subgroups and overall, derived by random-effects meta-analysis.
These are represented by a diamond of standard height, with the width indicating the 95% CI. See Table 13 for further details
relating to the estimates, and Table 14 for fuller details of the meta-analyses. Only estimates 3 and 16 are smoking adjusted.
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(page number not for citation purposes)marked differences between switchers and quitters in a
r a n g eo fc h a r a c t e r i s t i c s ,w i t ha d j u s t m e n ts u b s t a n t i a l l y
reducing the RR estimate from the age-adjusted estimate
of 1.92 (1.63–3.26).
Prostate cancer
Table17presentsdatafromfivecohortandtwocase-control
studies,allconductedinthe USA.Nosignificantassociation
betweenSTandprostatecancerisevidentinfivestudies,but
significant increases are seen in the Lutheran Brotherhood
Study [11] and, for current snuff users only, in the case-
control study by Hayes et al. [96]. Based on the five
studies which provide usable data, the overall estimate (see
Table 18 and Figure 9) is 1.20 (95% CI 1.03–1.40).
Prostate cancer is not considered smoking related [7,8],
and more information on its relationship with ST is
needed before any clear conclusion can be drawn.
Table 15: Lung cancer; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI)
e Adjustment factors
f
Cohort studies
US Veterans: Winn et al.
1982 [19]
ST Ever Never M
g 1 NA 0.60 (NA) age
NHANES I: Accortt et al.
2005 [22]
ST Ever Never F 2 4 6.80 (1.60–28.5) age, pov, race
CPS-I: Henley et al. 2005
[23]
ST Current Never M 3 18 1.08 (0.64–1 . 8 3 ) a g e ,a l c ,a s p ,b m i ,d i e t ,
edu, exer, occ, race
CPS-II: Henley et al. 2005
[23]
ST Current Never M 4 18 2.00 (1.23–3 . 2 4 ) a g e ,a l c ,a s p ,b m i ,d i e t ,
edu, exer, occ, race
ST Former 5 4 1.17 (0.43–3.14)
ST Ever 6 22 1.77 (1.14–2.74)
h
Chew only Current 7 12 1.97 (1.10–3.54)
Snuff only 8 2 2.08 (0.51–8.46)
Norway cohorts: Boffetta et
al. 2005 [26]
Snuff Current Any M 9 44 0.80 (0.58–1.11) age, smok
Former 10 28 0.80 (0.54–1.19)
Ever 11 72 0.80 (0.61–1.05)
Ever Never 12 3 0.96 (0.26–3.56) age
Swedish construction
workers: Luo et al. 2007
[32]
Snuff Ever Any M 13 NA 0.70 (0.60–0.70) age, bmi, smok
Current Never 14 15 0.80 (0.40–1.30) age, bmi
Former 15 3 0.90 (0.30–3.00)
Ever 16 18 0.80 (0.50–1.30)
Case-control studies
Doll and Hill 1952 [38] Chew Ever Any M 17 40 0.61 (0.41–0.92)
h none
Snuff 18 33 0.76 (0.48–1.21)
h
ST 19 73 0.66 (0.41–0.90)
h
Williams and Horm 1977
[55]
ST Ever Any M 20 36 0.69 (0.47–1.00)
h age, race, smok
F 21 1 0.38 (0.05–2.80)
h none
Wynder and Stellman 1977
[56]
Chew Ever Any M 22 117 1.26 (0.99–1.59)
h none
Snuff 23 35 1.25 (0.83–1.89)
h
ST 24 152 1.27 (1.03–1.57)
h
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 16, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eNA = not available.
fAbbreviations used: alc = alcohol consumption, asp = aspirin, bmi = body mass index, edu = education, exer = exercise, occ = occupation, pov =
poverty, smok = smoking.
gThe population included < 0.5% females.
hRR/OR and/or 95% CI estimated from data provided in the source.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any Overall data 9 (2, 3, 6, 11, 13, 19, 20, 21, 24) 0.96 (0.73–1.27) 53.2 85.0 < 0.001
Smoking-adjusted 6 (2, 3, 6, 11, 13, 20) 0.99 (0.71–1.37)
d 28.7 82.6 < 0.001
Never smokers 5 (2, 3, 6, 12, 16) 1.34 (0.80–2.23) 11.5 65.3 0.021
Any (USA) Overall data 6 (2, 3, 6, 20, 21, 24) 1.22 (0.82–1.83) 18.5 73.0 0.002
Smoking-adjusted 4 (2, 3, 6, 20) 1.38 (0.72–2.64) 16.5 81.9 0.001
Never smokers 3 (2, 3, 6) 1.79 (0.91–3.51) 6.2 67.8 0.045
Snuff (Scandinavia) Overall data 2 (11, 13) 0.71 (0.66–0.76) 0.9 0.0 0.354
Smoking-adjusted 2 (11, 13) 0.71 (0.66–0.76) 0.9 0.0 0.354
Never smokers 2 (12, 16) 0.82 (0.52–1.28) 0.1 0.0 0.798
aFor each study/sex, the RR/OR for ST from Table 15 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 15.
dTest for publication bias 0.05 ≤ P < 0.1.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
0.10 0.20 1.00 5.00 10.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
USA
  2 F NHANES I 6.80 (1.60, 28.50)
  3 M CPS-I 1.08 (0.64, 1.83)
  6 M CPS-II 1.77 (1.14, 2.74)
  20 M Williams and Horm 1977 0.69 (0.47, 1.00)
Subtotal (95% CI) 1.38 (0.72, 2.64)
SCANDINAVIA
  11 M Norway Cohorts 0.80 (0.61, 1.05)
  13 M Swedish construction workers 0.70 (0.60, 0.70)
Subtotal (95% CI) 0.71 (0.66, 0.76)
Total (95% CI) 0.99 (0.71, 1.37)
Figure 8
Smokeless tobacco and lung cancer by region (smoking-adjusted data). The six individual smoking-adjusted relative
risk (RR) and 95% confidence interval (CI) estimates, separated by region, are shown numerically and also graphically on a
logarithmic scale. They are sorted in order of year of publication within study type (cohort, case-control). In the graphical
representation individual RR estimates are indicated by a solid square, with the area of the square proportional to the weight
(inverse-variance) of the estimate. Also shown are the combined estimates, for the subgroups and overall, derived by random-
effects meta-analysis. These are represented by a diamond of standard height, with the width indicating the 95% CI.
See Table 15 for further details relating to the estimates, and Table 16 for fuller details of the meta-analyses.
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Table 19 summarises data from the Norway cohorts study
[26] and from 12 case-control studies. None of the case-
control studies were conducted after 1990, and with the
exception of two studies in Denmark [43,62], all were
carried out in the USA or Canada. The great majority of the
estimates are non-significant, and based on 10 smoking-
adjusted estimates the overall estimate (see Table 20 and
Figure 10) is 0.95 (95% CI 0.71–1.29). However, there is
significant heterogeneity due mainly to estimates 8, 12 and
22, which show a positive association, the last two of which
are significant, and estimate 31 which shows a significant
negative association.
Considered together, the data provide no real evidence
of an association between ST and bladder cancer.
Kidney cancer
Table 21 summarises evidence from one cohort and nine
case-control studies, none conducted in Sweden. The
estimates are generally based on small numbers of cases
Table 17: Prostate cancer; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Id. Cases
d Estimate (95%CI) Adjustment factors
e
Cohort studies
Lutheran Brotherhood: Hsing et al. 1990 [11] ST Ever Any 1 38 1.51 (1.03–2.19)
f age, smok
Never 2 10 4.50 (2.10–9.70) age
US Veterans: Hsing et al. 1991 [15] ST Ever Never 3 48 1.17 (0.88–1.56) age
Iowa cohort: Putnam et al. 2000 [20] ST Ever Any 4 NA no association age
NHANES I: Accortt et al. 2005 [22] ST Ever Never 5 19 1.20 (0.50–3.40) age, pov, race
Norway cohorts: IARC Monograph 37 1985 [14] ST Use Any 6 NA no association age, res, smok
Case-control studies
Williams and Horm 1977 [55] ST Ever Any 7 65 1.32 (0.94–1.84)
f age, race, smok
Hayes et al. 1994 [96] Chew Current Any 8 14 0.56 (0.30–1.06)
f none
Former 9 56 1.08 (0.75–1.55)
f
Ever 10 70 0.91 (0.67–1.25)
f
Snuff Current Any 11 10 6.74 (1.47–30.84)
f
Former 12 10 0.79 (0.36–1.74)
f
Ever 13 20 1.42 (0.75–2.67)
f
ST Current Any 14 24 0.92 (0.54–1.58)
g
Former 15 66 1.03 (0.74–1.43)
g
Ever 16 90 1.00 (0.75–1.33)
g
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 18, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eAbbreviations used: pov = poverty, res = area of residence, smok = smoking.
fRR/OR and/or 95% CI estimated from data provided in the source.
gRR/OR and/or 95% CI estimated from data provided in the source assuming that no one both chewed and used snuff.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
Table 18: Prostate cancer; meta-analysis results
Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any
d Overall data 5 (1, 3, 5, 7, 16) 1.20 (1.03–1.40) 3.3 0.0 0.506
Smoking-adjusted 4 (1, 3, 5, 7) 1.29 (1.07–1.55) 1.2 0.0 0.764
Never smokers 3 (2, 3, 5) 1.81 (0.76–4.30) 10.5 81.0 0.005
aFor each study/sex, the RR/OR for ST from Table 17 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 17.
dAll the available data for prostate cancer are from US studies.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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providing a statistically significant OR estimate exceeding
3.0, and other studies (and other estimates from the four
studies) showing notably smaller estimates, that are not
significant. Most of the meta-analysis estimates shown in
Table 22 (see also Figure 11) are elevated, with some
evidence of heterogeneity, but none are statistically sig-
nificant. Based on five smoking-adjusted estimates the
overall estimate for any ST use is 1.09 (0.69–1.71).
While there is a suggestion of a possible relationship,
more data are needed before any firm conclusions can be
reached.
Haematopoietic and lymphoid cancer
Table 23 summarises evidence from three cohort and
seven case-control studies for overall haematopoietic
cancer and for specific types. The only report of a
significant association is the OR of 4.0 (1.3–12.0) for
non-Hodgkin’s lymphoma in the case-control study of
Bracci and Holly [112]. However, the combined evidence
from the five studies (see Table 24 and Figure 12) for
non-Hodgkin’s lymphoma shows no significant relation-
ship (1.20, 0.83–1.75), though there is significant
heterogeneity (P = 0.01), due mainly to the Bracci and
Holly estimate. The evidence for other endpoints –
multiple myeloma, Hodgkin’sd i s e a s e ,l e u k a e m i a ,a n d
overall haematopoietic cancer – is more limited, and
does not suggest any relationship with ST use.
Other cancers
Table 25 summarises evidence from six cohort and four
case-control studies relating to cancers of types not
considered in Tables 3 to 24. Most of the results relate to
specific cancer types, though some relate to broader
groupings, such as genitourinary cancer and smoking-
related cancer, which include cancer types considered
earlier. Due to the variety of types, and the limited
numbers of estimates relating to any one type, no meta-
analyses were attempted. One of the studies [109] simply
reported a lack of association (with glioma), and the
remaining studies provided a total of 24 effect estimates
with CI. Six of these are statistically significant. Zahm et
al. [81] report an age-adjusted OR of 1.80 (95% CI 1.10–
2.90) for soft tissue sarcoma based on a case-control
study, though fail to confirm this later using data from
the US Veterans Study [17]. The Williams and Horm
study [55] provides a smoking-adjusted estimate of 4.18
(2.08–8.43) for cancer of the cervix, no other study
giving relevant results. Moore et al. [39], in a study
conducted in 1953, report a crude estimate of 2.41
(1.09–5.35) for cancer of the face, again an endpoint not
considered by others. Roosaar et al. [35] report an increased
risk of smoking-related cancer (1.6, 1.1–2.5) for never
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
  1 M Lutheran Brotherhood 1.51 (1.03, 2.19)
  3 M US Veterans 1.17 (0.88, 1.56)
  5 M NHANES I 1.20 (0.50, 3.40)
  7 M Williams and Horm 1977 1.32 (0.94, 1.84)
  16 M Hayes et al 1994 1.00 (0.75, 1.33)
Total (95% CI) 1.20 (1.03, 1.40)
Figure 9
Smokeless tobacco and prostate cancer (USA overall data). The five individual relative risk (RR) and 95% confidence
interval (CI) estimates, all for the USA, are shown numerically and also graphically on a logarithmic scale. They are sorted in
order of year of publication within study type (cohort, case-control). In the graphical representation individual RR estimates
are indicated by a solid square, with the area of the square proportional to the weight (inverse-variance) of the estimate. Also
shown are the combined estimates, for the subgroups and overall, derived by random-effects meta-analysis. These are
represented by a diamond of standard height, with the width indicating the 95% CI. See Table 17 for further details relating
to the estimates, and Table 18 for fuller details of the meta-analyses.
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ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI) Adjustment factors
e
Cohort studies
Norway cohorts: Boffetta et al. 2005 [26] Snuff Current Any M 1 40 0.72 (0.52–1.06) age, smok
Former 2 30 0.98 (0.66–1.47)
Ever 3 69 0.83 (0.62–1.11)
Case-control studies
Lockwood 1961 [43] ST Current Never M 4 2 0.35 (0.07–1.77)
f none
Wynder et al. 1963 [46] Chew Ever Any M 5 33 1.42 (0.82–2.47)
f none
Snuff 6 6 0.66 (0.23–1.88)
f
ST 7 39 1.21 (0.74–1.98)
g
Dunham et al. 1968 [48] ST Ever Never M 8 4 2.57 (0.52–12.54)
f race
F 9 3 0.58 (0.14–2.45)
f
Cole et al. 1971 [51] Chew Ever Any M 10 46 no association
h age
Snuff 11 3 no association
i
Williams and Horm 1977 [55] ST Ever Any M 12 29 1.67 (1.09–2.55)
f age, race, smok
F 13 1 0.82 (0.11–6.02)
f none
Wynder and Stellman 1977 [56] Chew Ever Any M 14 47 0.87 (0.63–1.21)
f none
Snuff 15 11 0.69 (0.36–1.31)
f
ST 16 58 0.82 (0.61–1.10)
g
Howe et al. 1980 [58] Chew Ever Any M 17 NA 0.90 (0.50–1.60) age, smok
Mommsen and Aagaard 1983 [62] Chew Ever Any M 18 39 1.70 (1.00–2.90) age, res
Hartge et al. 1985 [66] Chew Ever Never
j M 19 40 1.02 (0.67–1.54) age, race, res, smok
j
Snuff 20 11 0.77 (0.38–1.56)
ST 21 51 1.14 (0.80–1.61)
g none
Kabat et al. 1986 [69] Snuff Ever Never F 22 3 10.40 (1.07–101.46) none
Slattery et al. 1988 [77] Chew Ever Any M 23 20 0.76 (0.42–1.39) smok
k
Never 24 1 0.36 (0.05–2.82)
l none
Snuff Ever Any 25 16 0.92 (0.47–1.82) smok
k
Never 26 2 2.74 (0.45–16.69)
m none
ST Ever Any 27 36 0.82 (0.52–1.29)
g smok
k
Never 28 3 0.86 (0.24–3.07)
g none
Burch et al. 1989 [79] Chew Ever Any M 29 26 0.60 (0.34–1.06) age, res, smok
Snuff 30 9 0.47 (0.21–1.07)
ST 31 35 0.54 (0.34–0.87)
g
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 20, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eAbbreviations used: res = area of residence, smok = smoking.
fRR/OR and/or 95% CI estimated from data provided in the source.
gRR/OR and/or 95% CI estimated from data provided in the source assuming that no one both chewed and used snuff.
hAge-adjusted expected number of cases who chewed tobacco was given as 42.3 versus 46 observed.
iAge-adjusted expected number of cases who used snuff was given as 2.9 versus 3 observed.
jEstimates were for never cigarette smokers adjusted for other tobacco use.
kAdjusted for age started to smoke; results adjusted for smoking group, pack years or years stopped are similar.
lT h es o u r c ep a p e rg a v e2 . 7 8( 0 . 3 8 –20.20) which is incorrect based on the numbers in the 2 × 2 table.
mThe source paper gave 2.73 (0.48–15.57) which is incorrect based on the numbers in the 2 × 2 table.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any Overall data 14 (3, 4, 7, 8, 9, 12, 13, 16, 17, 18, 21,
22, 27, 31)
1.00 (0.80–1.25) 28.7 54.7 0.007
Smoking-adjusted 10 (3, 4, 8, 9, 12, 17, 21, 22, 27, 31) 0.95 (0.71–1.29) 22.3 59.6 0.008
Never smokers 6 (4, 8, 9, 21, 22, 28) 1.10 (0.60–2.02) 7.7 35.1 0.173
Any (USA) Overall data 9 (7, 8, 9, 12, 13, 16, 21, 22, 27) 1.11 (0.85–1.45) 14.8 45.9 0.064
Smoking-adjusted 6 (8, 9, 12, 21, 22, 27) 1.24 (0.83–1.85) 10.4 52.1 0.064
Never smokers 5 (8, 9, 21, 22, 28) 1.25 (0.69–2.26) 5.6 29.2 0.227
Snuff (Scandinavia)
d Overall data 1 (3) 0.83 (0.62–1.11) –– –
Smoking-adjusted 1 (3) 0.83 (0.62–1.11) –– –
aFor each study/sex, the RR/OR for ST from Table 19 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 19.
dThere are no data for never smokers for snuff in Scandinavia.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
0.10 0.20 1.00 10.00 20.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
USA
  8 M Dunham et al 1968 2.57 (0.52,12.54)
  9 F Dunham et al 1968 0.58 (0.14, 2.45)
  12 M Williams and Horm 1977 1.67 (1.09, 2.55)
  21 M Hartge et al 1985 1.14 (0.80, 1.61)
  22 F Kabat et al 1986 10.40 (1.07,101.46)
  27 M Slattery et al 1988 0.82 (0.52, 1.29)
Subtotal (95% CI) 1.24 (0.83, 1.85)
SCANDINAVIA
  3 M Norway cohorts 0.83 (0.62, 1.11)
  4 M Lockwood 1961 0.35 (0.07, 1.77)
Subtotal (95% CI) 0.79 (0.53, 1.18)
OTHER
  17 M Howe et al 1980 0.90 (0.50, 1.60)
  31 M Burch et al 1989 0.54 (0.34, 0.87)
Subtotal (95% CI) 0.68 (0.41, 1.11)
Total (95% CI) 0.95 (0.71, 1.29)
Figure 10
Smokeless tobacco and bladder cancer by region (smoking-adjusted data). The 10 individual smoking-adjusted
relative risk (RR) and 95% confidence interval (CI) estimates, separated by region, are shown numerically and also graphically
on a logarithmic scale. They are sorted in order of year of publication within study type (cohort, case-control). In the graphical
representation individual RR estimates are indicated by a solid square, with the area of the square proportional to the weight
(inverse-variance) of the estimate. Also shown are the combined estimates, for the subgroups and overall, derived by random-
effects meta-analysis. These are represented by a diamond of standard height, with the width indicating the 95% CI.
See Table 19 for further details relating to the estimates, and Table 20 for fuller details of the meta-analyses.
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ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI) Adjustment factors
e
Cohort studies
Norway cohorts: Boffetta et al. 2005 [26] Snuff Current Any M 1 9 0.47 (0.23–0.94) age, smok
Former 2 13 1.17 (0.63–2.16)
Ever 3 22 0.72 (0.44–1.18)
Case-control studies
Bennington and Laubscher 1968 [47] Chew Use Any M 4 5 1.22 (0.39–3.85)
f none
Never 5 5 4.80 (1.18–19.59)
f age
Armstrong et al. 1976 [53] ST Current Any M 6 6 0.98 (0.30–3.15)
f none
Former 7 6 0.73 (0.24–2.20)
f
Ever 8 12 0.84 (0.37–1.92)
f
Williams and Horm 1977 [55] ST Ever Any M 9 3 0.59 (0.18–1.90)
f none
F 10 1 1.26 (0.17–9.33)
f
McLaughlin et al. 1984 [65] Chew Use Any M 11 NA 0.40 (0.10–2.60) age, smok
Snuff 12 NA 1.70 (0.50–6.00)
ST 13 NA 1.00 (0.37–2.68)
g
Goodman et al. 1986 [68] Chew Ever Any M 14
h 13 4.00 (1.13 – 14.17) age, hosp, race, tadm
Asal et al. 1988 [73] Snuff Use Any M 15
i NA 3.60 (1.20–13.30) age, hosp, race, tadm
16
j NA no association age, race, tadm
McLaughlin et al. 1995 [99] ST Use Never M+F 17 11 1.30 (0.60–3.10) age, bmi, res, sex
Muscat et al. 1995 [100] Chew Ever Any M 18 14 3.20 (1.10–8.70) age, edu
Yuan et al. 1998 [106] ST Ever Any M+F 19 32 1.02 (0.56–1.85) age, edu, smok
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 22, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eAbbreviations used: bmi = body mass index, edu = education, hosp = hospital, res = residence, smok = smoking, tadm = time of admission.
fRR/OR and/or 95% CI estimated from data provided in the source.
gEstimated assuming ORs for chewing and snuff are independent.
hThe authors also report the results of an analysis adjusting for the effects of the matching factors, body mass index, decaffeinated coffee use and
continuous pack-years of cigarette smoking. The authors estimated an OR (95% CI) of 0.87 (0.15–5.14) for the effect of chewing among never
smokers of cigarettes, and of 26.00 (4.41–153.00) for the joint effect of pack-years cigarette smoking and chewing tobacco use. These results could
not readily be incorporated into the meta-analyses as no overall estimate for chewing tobacco use adjusted for cigarette smoking was available.
iAnalysis uses hospital controls.
jAnalysis uses population controls.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
Table 22: Kidney cancer; meta-analysis results
Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any Overall data 11 (3, 4, 8, 9, 10, 13, 14, 15, 17, 18, 19) 1.23 (0.86–1.76)
d 16.5 39.2 0.087
Smoking-adjusted 5 (3, 5, 13, 17, 19) 1.09 (0.69–1.71)
e 6.9 41.9 0.142
Never smokers 2 (5, 17) 2.19 (0.63–7.70) 2.5 59.6 0.116
Any (USA) Overall data 8 (4, 9, 10, 13, 14, 15, 18, 19) 1.52 (0.94–2.46) 11.1 37.1 0.133
Smoking-adjusted 3 (5, 13, 19) 1.41 (0.64–3.10) 4.2 51.8 0.125
Never smokers 1 (5) 4.80 (1.18–19.56) –– –
Snuff (Scandinavia)
f Overall data 1 (3) 0.72 (0.44–1.18) –– –
Smoking-adjusted 1 (3) 0.72 (0.44–1.18) –– –
aFor each study/sex, the RR/OR for ST from Table 21 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 21.
dTest for publication bias 0.05 ≤ P < 0.1.
eTest for publication bias 0.01 ≤ P<0 . 0 5 .
fThere are no available data for never smokers using snuff in Scandinavia.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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smoker and non-smokers combined (1.1, 0.8–1.4). Finally,
based on the Swedish construction workers study, Oden-
bro et al. [29,33] report that snuff use is associated with a
reduced smoking-adjusted risk of cutaneous squamous cell
carcinoma (0.64, 0.44–0.95) and, in never smokers, with a
reduced risk of melanoma (0.65, 0.52–0.82). These
isolated reports need confirmation in other studies before
any effect of ST can reliably be inferred. A study in
Cherokee women [125,126] which shows no association of
breast cancer with ever ST use, with an odds ratio adjusted
for age at diagnosis estimated as 1.24 (0.26–6.02), is not
considered in Table 25 as the study is of cross-sectional
design. It contributes little to the evidence.
Overall cancer risk
As shown in Table 26, ST use has been related to overall
cancerrisk infive cohortstudies and one case-control study.
Two of the 12 estimates shown are smoking-adjusted
estimates for smokers and non-smokers combined, one
(estimate 10) showing no association at all (RR = 1.00) and
theother(estimate12,basedonthecase-controlstudy[89])
a reduced OR of 0.64 (95% CI 0.53–0.78). The remaining
10estimates,allfromcohortstudies,andalladjustedforage
and various other potential confounders, are for never
smokers.AsshowninTable27andFigure13,thecombined
estimate for all the smoking-adjusted data is not elevated
(0.98, 0.84–1.15, n = 7). However, the combined estimate
forneversmokers,whichexcludesthelowestimatefromthe
case-control study, is a significant 1.10 (1.02–1.19, n =6 ) .
The estimate for never smokers is similar for the US data
(1.10, 1.01–1.20, n = 4) and the Scandinavian snuff data
(1.10, 0.94–1.29, n = 2). The data are consistent with any
excess risk of cancer in ST users being small.
Publication bias
There are 49 meta-analyses presented that combine five or
more effect estimates. The test of publication bias [121]
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
USA
  5 M Bennington and Laubscher 1968 4.80 (1.18,19.59)
  13 M McLaughlin et al 1984 1.00 (0.37, 2.68)
  19 M+F Yuan et al 1998 1.02 (0.56, 1.85)
Subtotal (95% CI) 1.41 (0.64, 3.10)
SCANDINAVIA
  3 M Norway Cohorts 0.72 (0.44, 1.18)
Subtotal (95% CI) 0.72 (0.44, 1.18)
OTHER
  17 M+F McLaughlin et al 1995 1.30 (0.60, 3.10)
Subtotal (95% CI) 1.30 (0.57, 2.95)
Total (95% CI) 1.09 (0.69, 1.71)
Figure 11
Smokeless tobacco and kidney cancer by region (smoking-adjusted data). The five individual smoking-adjusted
relative risk (RR) and 95% confidence interval (CI) estimates, separated by region, are shown numerically and also graphically
on a logarithmic scale. They are sorted in order of year of publication within study type (cohort, case-control). In the graphical
representation individual RR estimates are indicated by a solid square, with the area of the square proportional to the weight
(inverse-variance) of the estimate. Also shown are the combined estimates, for the subgroups and overall, derived by random-
effects meta-analysis. These are represented by a diamond of standard height, with the width indicating the 95% CI.
See Table 21 for further details relating to the estimates, and Table 22 for fuller details of the meta-analyses.
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significant at P < 0.05, similar to the numbers one would
expect by chance. Both the significant cases (see Tables
22 and 24) arise due to a single high effect estimate, with
the other estimates included in the analysis relatively close
to 1.0.
Sensitivity analyses
Table 28 shows the effect on the smoking-adjusted
analyses of successively removing those RR/OR estimates
with the largest Q
2 values. Results are only shown for
those cancers where significant (P < 0.05) heterogeneity
was evident, and removal continues until no significant
Table 23: Haematopoietic and lymphoid cancer; individual effect (relative risk/odds ratio) estimates
ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI) Adjustment factors
e
Cohort studies
US veterans: Heinemann et al.
1992 [16]
- multiple myeloma ST Use Never M
f 1 6 1.00 (0.40–2.30) age, time, yriv
CPS-II: Henley et al. 2005 [23]
- any haematopoietic cancer ST Current Never M 2 19 0.95 (0.60–1.51) age, alc, asp, bmi, diet, edu, exer, occ, race
Former 3 9 1.16 (0.60–2.25)
Ever 4 28 1.01 (0.69–1.48)
g
Swedish construction workers:
Fernberg et al. 2006 [30]
- non-Hodgkin's lymphoma Snuff Ever Never M 5 66 0.77 (0.59–1.01) age, bmi
- Hodgkin's disease Snuff Ever Never M 6 15 0.88 (0.49–1.58)
Swedish construction workers:
Fernberg et al. 2007 [31]
- leukaemia Snuff Ever Never M 7 NA no increased risk age, bmi
- multiple myeloma Snuff Ever Never M 8 NA no increased risk age, bmi
Case-control studies
Williams and Horm 1977 [55]
- any haemopoietic cancer ST Ever Any M 9 13 0.63 (0.35–1.14)
g none
F 10 3 1.01 (0.31–3.29)
g
Lindquist et al. 1987 [72]
- leukaemia Snuff Ever Any M+F 11 18 0.94 (0.47–1.89)
h a g e ,r e s ,s e x
Morris Brown et al. 1992 [87]
- leukaemia ST Use Never M 12 24 1.80 (0.90–3.30)
i age, alc, res
Morris Brown et al. 1992 [88]
- non-Hodgkin's lymphoma ST Use Never M 13 19 1.30 (0.70–2.50)
j age, res
- multiple myeloma ST Use Never M 14 5 1.90 (0.50–6.60) age, res
Hardell et al. 1994 [95]
- non-Hodgkin's lymphoma Snuff Use Any M 15 35 1.50 (0.90–2.50) none
Schroeder et al. 2002 [110]
- non-Hodgkin's lymphoma Chew Ever Any M 16 19 1.23 (0.80–1.88)
k age, res
Snuff 17 19 0.93 (0.61–1.41)
k
ST 18 38 1.06 (0.77–1.45)
l
Bracci and Holly 2005 [112]
- non-Hodgkin's lymphoma ST Ever Never M 19 7 4.00 (1.30–12.00) age, alc, edu
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 24, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eAbbreviations used: alc = alcohol, asp = aspirin, bmi = body mass index, edu = education, exer = exercise, occ = occupation, smok = smoking, tadm
= time of admission, yriv = year of interview.
fThe population included < 0.5% females.
gEstimated from data on limited number of exposed cases for eight sub-types of haemopoietic cancer.
hRR/OR and/or 95% CI estimated from data provided in the source.
iData for six subtypes of leukaemia were also provided, but none were statistically significant.
jData for five subtypes of non-Hodgkin's lymphoma were also provided, but none were statistically significant.
kEstimated from data for t (14,18)-positive and t (14,18)-negative cases.
lEstimated from the results for chew and snuff, assuming that no one both chewed and used snuff.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any Overall data 5 (5, 13, 15, 18, 19) 1.20 (0.83–1.75)
d 12.8 68.8 0.012
Smoking-adjusted 3 (5, 13, 19) 1.35 (0.62–2.94) 9.5 78.9 0.009
Never smokers 3 (5, 13, 19) 1.35 (0.62–2.94) 9.5 78.9 0.009
Any (USA) Overall data 3 (13, 18, 19) 1.45 (0.81–2.59) 5.2 61.2 0.076
Smoking-adjusted 2 (13, 19) 2.07 (0.70–6.13) 3.0 66.2 0.085
Never smokers 2 (13, 19) 2.07 (0.70–6.13) 3.0 66.2 0.085
Snuff (Scandinavia) Overall data 2 (5, 15) 1.04 (0.54–1.98) 5.1 80.5 0.024
Smoking-adjusted 1 (5) 0.77 (0.59–1.01) –– –
Never smokers 1 (5) 0.77 (0.59–1.01) –– –
aFor each study/sex, the RR/OR for ST from Table 23 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 23.
dTest for publication bias 0.01 ≤ P < 0.05.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
USA
  13 M Morris Brown et al 1992 1.30 (0.70, 2.50)
  18 M Schroeder et al 2002 1.06 (0.77, 1.45)
  19 M Bracci and Holly 2005 4.00 (1.30, 12.00)
Subtotal (95% CI) 1.45 (0.81, 2.59)
SCANDINAVIA
  5 M Swedish construction workers 0.77 (0.59, 1.01)
  15 M Hardell et al 1994 1.50 (0.90, 2.50)
Subtotal (95% CI) 1.04 (0.54, 1.98)
Total (95% CI) 1.20 (0.83, 1.75)
Figure 12
Smokeless tobacco and non-Hodgkin's lymphoma by region (overall data). The five individual relative risk (RR) and
95% confidence interval (CI) estimates, separated by region, are shown numerically and also graphically on a logarithmic scale.
They are sorted in order of year of publication within study type (cohort, case-control). In the graphical representation
individual RR estimates are indicated by a solid square, with the area of the square proportional to the weight (inverse-
variance) of the estimate. Also shown are the combined estimates, for the subgroups and overall, derived by random-effects
meta-analysis. These are represented by a diamond of standard height, with the width indicating the 95% CI. See Table 23 for
further details relating to the estimates, and Table 24 for fuller details of the meta-analyses. Only estimates 5, 13 and
19 are smoking-adjusted.
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ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI) Adjustment factors
e
Cohort studies
US Veterans: Zahm et al. 1992 [17]
- soft tissue sarcoma ST Ever Any M
f 12 1 0 . 8 5 ( 0 . 5 3 –1.36) age, smok, time
NHANES I: Accortt et al. 2005 [22]
- breast cancer ST Ever Never F 2 5 1.80 (0.50–6.50) age, pov, race
CPS-I: Henley et al. 2005 [23]
- genitourinary cancer ST Current Never M 3 98 0.97 (0.77–1.22) age, alc, asp, bmi, diet, edu, exer,
occ, race
CPS-II: Henley et al. 2005 [23]
- genitourinary cancer ST Current Never M 4 44 1.15 (0.85–1.56) age, alc, asp, bmi, diet, edu, exer,
occ, race
Former 5 16 0.97 (0.59–1.59)
Ever 6 60 1.10 (0.84–1.42)
g
Swedish construction workers: Odenbro
et al. 2005 [29]
- cutaneous squamous cell carcinoma Snuff Ever Any M 7 29 0.64 (0.44–0.95) age, smok
Swedish construction workers: Odenbro
et al. 2007 [33]
- melanoma
h Snuff Ever Never M 8 96 0.65 (0.52–0.82) age, bir, bmi
Uppsala County: Roosaar et al. 2008 [35]
- smoking related cancer Snuff Ever Any M 9 71 1.10 (0.80–1.40) age, alc, res, smok, time
Never 10 39 1.60 (1.10–2.50) age, alc, res, time
Case-control studies
Moore et al. 1953 [39]
- cancer of face ST Use Any M 11 49 2.41 (1.09–5.35) none
Williams and Horm 1977 [55]
- breast cancer ST Ever Any F 12 11 0.60 (0.31–1.17)
g age, smok
- cancer of male genitalia ST Ever Any M 13 2 0.47 (0.11–1.94)
g None
- cancer of cervix ST Ever Any F 14 10 4.18 (2.08–8.43)
g age, smok
- cancer of uterus ST Ever Any F 15 7 1.92 (0.86–4.28)
g age, smok
- cancer of ovary ST Ever Any F 16 2 0.77 (0.19–3.21)
g none
- cancer of vulva ST Ever Any F 17 1 2.06 (0.28–15.41)
g none
- connective tissue ST Ever Any M 18 1 0.26 (0.04–1.93)
g none
- melanoma ST Ever Any M 19 1 0.30 (0.04–2.18)
g none
- nervous system cancer ST Ever Any M 20 1 0.18 (0.02–1.32)
g none
F 21 2 3.28 (0.77–13.99)
g
- thyroid cancer ST Ever Any M 22 1 0.36 (0.05–2.69)
g none
F 23 1 0.73 (0.10–5.38)
g
Zahm et al. 1989 [81]
- soft tissue sarcoma ST Ever Any M 24 28 1.80 (1.10–2.90) Age
Zheng et al. 2001 [109]
- brain cancer (glioma) Chew Use Any M+F 25 NA no association NA
Snuff 26 NA no association
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number, and 'Cases' is the number of cases in ST users as defined. NA = not available.
eAbbreviations used: alc = alcohol, asp = aspirin, bir = birth cohort, bmi = body mass index, edu = education, exer = exercise, occ = occupation,
pov = poverty, res = area of residence, smok = smoking. NA = not available.
fThe population included < 0.5% females.
gRR/OR and/or 95% CI estimated from data provided in the source.
hIncluding melanoma in situ
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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ST use RR/OR
Source
a Type
b Exposure
c Smoking Sex Id. Cases
d Estimate (95%CI)
d Adjustment factors
e
Cohort studies
NHANES I: Accortt et al. 2005 [22] ST Ever Never M 1 38 0.80 (0.40–1.60) age, pov, race
F 2 26 1.20 (0.70–2.10) age, pov, race
CPS-I: Henley et al. 2005 [23] ST Current Never M 3 357 1.07 (0.95–1.20) age, alc, asp, bmi, diet,
edu, exer, occ, race
CPS-II: Henley et al. 2005 [23] ST Current Never M 4 162 1.19 (1.02–1.40) age, alc, asp, bmi, diet,
edu, exer, occ, race
ST Former 5 57 1.04 (0.80–1.36)
ST Ever 6 219 1.15 (1.00–1.32)
f
Chew only Current 7 113 1.23 (1.02–1.49)
Snuff only Current 8 14 0.93 (0.55–1.57)
Swedish construction workers:
Bolinder et al. 1994 [28]
Snuff Current Never M 9 96 1.10 (0.90–1.40) age, res
Uppsala County: Roosaar et al.
2008 [35]
Snuff Ever Any M 10 237 1.00 (0.87–1.15) age, alc, res, smok, time
Never 11 138 1.10 (0.90–1.40) age, alc, res, time
Case-control studies
Sterling et al. 1992 [89] ST Ever Any M+F 12 2,498
g 0.64 (0.53–0.78)
f age, alc, occ, race, sex,
smok
aFuller details of the studies are given in Tables 1 and 2.
bST implies smokeless tobacco unspecified, or combined snuff use or chewing.
cEver, former and current ST use were compared with never ST. Use indicates timing not given and comparison is with non use.
d'Id.' is the RR/OR identification number used in Table 27, and 'Cases' is the number of cases in ST users as defined.
eAbbreviations used: alc = alcohol, asp = aspirin, bmi = body mass index, edu = education, exer = exercise, occ = occupation, pov = poverty,
res = area of residence, smok = smoking.
fRR/OR and/or 95% CI estimated from data provided in the source.
gNumber of cases estimated from data provided in the source.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
Table 27: Overall cancer; meta-analysis results
Heterogeneity
Type of ST (region)
a Adjustments/restrictions
b Number of estimates (RR/OR ids)
c Random-effects RR/OR (95% CI) c
2 I
2 P(c
2)
Any Overall data 7 (1, 2, 3, 6, 9, 10, 12) 0.98 (0.84–1.15) 27.1 77.9 < 0.001
Smoking-adjusted 7 (1, 2, 3, 6, 9, 10, 12) 0.98 (0.84–1.15) 27.1 77.9 < 0.001
Never smokers 6 (1, 2, 3, 6, 9, 11) 1.10 (1.02–1.19) 1.5 0.0 0.911
Any (USA) Overall data 5 (1, 2, 3, 6, 12) 0.95 (0.74–1.22) 26.5 84.9 < 0.001
Smoking-adjusted 5 (1, 2, 3, 6, 12) 0.95 (0.74–1.22) 26.5 84.9 < 0.001
Never smokers 4 (1, 2, 3, 6) 1.10 (1.01–1.20) 1.5 0.0 0.679
Snuff (Scandinavia) Overall data 2 (9, 10) 1.03 (0.91–1.16) 0.5 0.0 0.475
Smoking-adjusted 2 (9, 10) 1.03 (0.91–1.16) 0.5 0.0 0.475
Never smokers 2 (9, 11) 1.10 (0.94–1.29) 0.0 0.0 1.000
aFor each study/sex, the RR/OR for ST from Table 26 was included if available, otherwise that for chewing tobacco or snuff was used.
bSmoking-adjusted includes estimates for smokers and non-smokers combined, adjusted for smoking if available, and estimates for never smokers
otherwise.
cThe actual estimates included are identified by their RR/OR identification numbers as given in Table 26.
CI = confidence interval; ST = smokeless tobacco; OR = odds ratio; RR = relative risk.
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(page number not for citation purposes)heterogeneity is seen. For pancreatic, lung and bladder
cancer and for non-Hodgkin’s lymphoma, only relatively
high estimates are removed, and the random-effects
estimate decreased, though only for lung cancer was the
estimate now significantly below 1.0. For digestive
cancer, the effect is to increase the estimate, but the
significance is unchanged. For overall cancer, the effect is
also to increase the estimate, here to marginal signifi-
cance, 1.07 (1.00–1.15). For oropharyngeal cancer, the
original substantial heterogeneity (P < 0.001) is seen to
be due mainly to four estimates, three high and one low.
The excess decreases from a significant 1.36 (1.04–1.77)
to a non-significant 1.17 (0.95–1.45) after the removal
of these estimates.
Similar analyses for the overall data (not shown) were also
carried out. They also did not help to demonstrate any
clear effect of ST on risk. For oropharyngeal cancer, where
heterogeneity is very marked indeed, this is mainly due to
estimates with atypically high values (see particularly
Table 3 id. numbers 1, 15, 21, 22, 34 and 35).
Table 29 compares the smoking-adjusted meta-analysis
estimates reported earlier with those recalculated pre-
ferring, where there was a choice, estimates for current ST
use to those for ever use or unspecified ST use. The meta-
analyses for the 12 cancers considered are based on a
total of 83 effect estimates. In only 19 of these (23%) did
the change in order of preference affect the estimate
chosen. For 10 of these the estimate for current ST use is
higher than that for ever or unspecified use, for eight it is
lower, and for the other the two estimates are the same.
The largest change is for pancreatic cancer in the Swedish
construction workers study [32], where the selected RR
value increases from 0.90 (0.70–1.20) in the original
analysis to 2.10 (1.20–3.60) in the sensitivity analysis.
However most of the changes, in either direction, are
quite minor.
0.20 0.40 1.00 2.50 5.00
Id, Sex, Study name Relative Ris Relative Riskk
95% CI 95% CI
USA
  1 M NHANES I 0.80 (0.40, 1.60)
  2 F NHANES I 1.20 (0.70, 2.10)
  3 M CPS-I 1.07 (0.95, 1.20)
  6 M CPS-II 1.15 (1.00, 1.32)
  12 M+F Sterling et al 1992 0.64 (0.53, 0.78)
Subtotal (95% CI) 0.95 (0.74, 1.22)
SCANDINAVIA
  9 M Swedish construction workers 1.10 (0.90, 1.40)
  10 M Uppsala County 1.00 (0.87, 1.15)
Subtotal (95% CI) 1.03 (0.91, 1.16)
Total (95% CI) 0.98 (0.84, 1.15)
Figure 13
Smokeless tobacco and overall cancer by region (smoking-adjusted data). The seven individual smoking-adjusted
relative risk (RR) and 95% confidence interval (CI) estimates, separated by region, are shown numerically and also graphically
on a logarithmic scale. They are sorted in order of year of publication within study type (cohort, case-control). In the graphical
representation individual RR estimates are indicated by a solid square, with the area of the square proportional to the weight
(inverse-variance) of the estimate. Also shown are the combined estimates, for the subgroups and overall, derived by
random-effects meta-analysis. These are represented by a diamond of standard height, with the width indicating the 95% CI.
See Table 26 for further details relating to the estimates, and Table 27 for fuller details of the meta-analyses.
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(page number not for citation purposes)For 8 of the 12 cancers, the change to the meta-analysis
estimate from the altered preference is very small, by ± 0.02
at most. For oropharyngeal cancer it increases by 0.06, for
larynx cancer by 0.11, for lung cancer by 0.12 and for
pancreatic cancer 0.15. None of these changes materially
affect the significance or the interpretation. Although there
is perhaps a slight indication that associations may be
stronger for current use, the tendency of most studies to
report results only for ever or unspecified ST use limits the
extent to which this can be investigated. Changing
preferences did not materially affect the heterogeneity of
the estimates. The effect of similarly changing the
preference on the other meta-analyses shown earlier (for
example, for never smokers or by country) also did not
materially affect the results obtained (data not shown).
Meta-regression analyses
For oropharyngeal cancer, based on the 19 smoking-
adjusted estimates, where the deviance (heterogeneity c
2)
is 69.5 (P < 0.001), significant reductions in deviance in
‘one factor at a time’ analysis are seen for period by study
type (P < 0.001, drop in deviance 46.7 on 2 d.f.), sex (P =
0.020, drop 26.9 on 2 d.f.) and region (P = 0.014, drop
21.3 on 1 d.f.). However, the tendency for estimates to be
high in females and the USA was no longer significant after
adjustment for period by study type, this relationship
reflecting the tendency for estimates to be high in case-
control studies published before 1990, low in case-control
studies published after 1990, and intermediate in pro-
spective studies (see Figure 2).
Based on the 41 overall estimates (whether smoking-
adjusted or not) for oropharyngeal cancer, where the
deviance is 335.6 (P < 0.001), the most significant factor is
sex (P = 0.004, drop 83.4 on 2 d.f.). Though drops in
deviance of 20 or more are also seen for region, period by
study type and smoking status, with estimates high for
females, USA, old case-control studies and data unadjusted
for smoking, no other factor is significant at P < 0.05 after
adjustment for sex. The high deviance of 335.6 is clearly
due to very high Q
2 values for some estimates, and further
analyses were run excluding these estimates (ids 1, 7, 21,
22 and 34 in Table 3). This reduces the deviance
considerably, to 84.4, though it is still highly significant
(P < 0.001). However, again sex was the most significant
factor (P = 0.02), with no further factor significant at
P < 0.05 after adjusting for sex.
Meta-regression analyses were not attempted for larynx,
n a s a lo rp r o s t a t ec a n c e ro rf o ro v e r a l ld i g e s t i v ec a n c e ro r
Table 28: Sensitivity analyses for smoking-adjusted data. Effect of removing relative risk/odds ratio estimates with largest Q
2 values on
heterogeneity and random-effects meta-analysis estimates
Cancer (number of estimates) RR/OR estimate removed Heterogeneity Random-effects RR/OR (95% CI)
Id. RR/OR Q
2 c
2 P
Oropharyngeal (n = 19) 69.5 < 0.001 1.36 (1.04–1.77)
35 2.67 (1.83–3.90) 15.6 52.2 < 0.001 1.27 (0.99–1.64)
13 2.05 (1.48–2.83) 12.2 37.9 0.002 1.20 (0.94–1.52)
43 6.20 (1.90–19.80) 8.9 28.9 0.017 1.11 (0.90–1.38)
7 0.70 (0.50–0.90) 6.2 21.0 0.101 1.17 (0.95–1.45)
Pancreatic (n = 7) 21.2 0.002 1.07 (0.71–1.60)
5 1.67 (1.12–2.50) 6.0 13.8 0.017 0.95 (0.63–1.46)
1 1.70 (0.90–3.10) 4.1 9.2 0.057 0.83 (0.54–1.28)
Overall digestive (n = 5) 17.3 0.002 0.86 (0.59–1.25)
19 0.40 (0.24–0.69) 13.3 3.1 0.382 1.14 (0.99–1.33)
Lung (n =6 ) 28.7 < 0.001 0.99 (0.71–1.37)
6 1.77 (1.14–2.74) 15.5 12.7 0.013 0.83 (0.63–1.08)
2 6.80 (1.60–28.5) 9.4 3.3 0.343 0.72 (0.65–0.80)
Bladder (n = 10) 22.3 0.008 0.95 (0.71–1.29)
12 1.67 (1.09–2.55) 6.9 14.3 0.074 0.86 (0.65–1.13)
Non-Hodgkin's lymphoma (n =3 )
9.5 0.009 1.35 (0.62–2.95)
19 4.00 (1.30–12.0) 6.9 2.2 0.137 0.92 (0.57–1.50)
Overall (n = 7) 27.1 < 0.001 0.98 (0.84–1.15)
12 0.64 (0.53–0.78) 21.4 2.8 0.725 1.07 (1.00–1.15)
CI = confidence interval; OR = odds ratio; RR = relative risk.
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(page number not for citation purposes)non-Hodgkin’s lymphoma because of insufficient num-
bers of estimates, or for oesophageal, stomach and
kidney cancer because of lack of heterogeneity. For
pancreatic and bladder cancer, none of the factors
investigated significantly (at P < 0.05) explained the
heterogeneity. For overall cancer, study type was
significant (P = 0.001), but this merely reflected the
low estimate for the single case-control study, evident
Table 29: Further sensitivity analyses for smoking-adjusted data. Effect of preferring estimates for current smokeless tobacco use to
those for ever or unspecified smokeless tobacco use
Heterogeneity
Cancer Analysis
a N (nc)
b Random-effects RR/OR (95% CI) c
2 P
Oropharyngeal Table 4 19 1.36 (1.04–1.77) 69.5 < 0.001
Sensitivity (5) 1.42 (1.10–1.84) 51.1 < 0.001
Oesophageal Table 6 7 1.13 (0.95–1.36) 4.4 0.623
Sensitivity (2) 1.11 (0.92–1.34) 4.1 0.665
Stomach Table 8 8 1.03 (0.88–1.20) 10.3 0.173
Sensitivity (2) 1.01 (0.86–1.19) 10.4 0.165
Pancreatic Table 10 7 1.07 (0.71–1.60) 21.5 0.001
Sensitivity (2) 1.22 (0.75–2.01) 23.1 < 0.001
Overall digestive Table 12 5 0.86 (0.59–1.25) 17.3 0.002
Sensitivity (1) 0.85 (0.57–1.27) 17.3 0.002
Larynx Table 14 2 1.34 (0.61–2.95) 4.0 0.044
Sensitivity (1) 1.45 (0.73–2.88) 2.5 0.116
Lung Table 16 6 0.99 (0.71–1.37) 28.7 < 0.001
Sensitivity (3) 1.11 (0.73–1.69) 20.6 < 0.001
Prostate Table 18 4 1.29 (1.07–1.55) 1.2 0.764
Sensitivity (0)
Bladder Table 20 10 0.95 (0.71–1.29) 22.3 0.008
Sensitivity (1) 0.94 (0.68–1.29) 23.7 0.005
Kidney Table 22 5 1.09 (0.69–1.71) 6.9 0.142
Sensitivity (1) 1.07 (0.60–1.91) 9.6 0.048
Non-Hodgkin's lymphoma Table 24 3 1.35 (0.62–2.94) 9.5 0.009
Sensitivity (0)
Overall Table 27 7 0.98 (0.84–1.15) 27.1 < 0.001
Sensitivity (1) 0.99 (0.83–1.17) 27.9 < 0.001
aFor each cancer the first line repeats the original results preferring ever or unspecified ST use shown in the Table indicated, while the second line
presents the results of the sensitivity analysis preferring current ST use.
bN is the number of estimates included in the original and sensitivity analyses; nc is the number of changed estimates. For each cancer, the
identification numbers for the estimates (shown in the Table indicated) included in the sensitivity analysis are shown below, with those not used in the
original analysis in italic.
Oropharyngeal (Table 3): 2, 3, 4, 8, 11, 13, 18, 26, 35, 43, 48, 51, 55, 56, 58, 61, 70, 74, 75
Oesophageal (Table 5): 3, 6, 10, 11, 19, 20, 23
Stomach (Table 7): 1, 4, 7, 10, 14, 17, 19, 21
Pancreatic (Table 9): 1, 3, 8, 11, 16, 18, 23
O v e r a l ld i g e s t i v e( T a b l e1 1 ) :4 ,5 ,6 ,7 ,1 9
Larynx (Table 13): 3, 14
Lung (Table 15): 2, 3, 4, 9, 14, 20
Prostate (Table 17): 1, 3, 5, 7
Bladder (Table 19): 1, 4, 8, 9, 12, 17, 21, 22, 27, 31
Kidney (Table 21): 1, 5, 13, 17, 19
Non-Hodgkin's lymphoma (Table 23): 5, 13, 19
Overall cancer (Table 26): 1, 2, 3, 4, 9, 10, 12
CI = confidence interval; OR = odds ratio; RR = relative risk.
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(page number not for citation purposes)also in the sensitivity analysis shown in Table 28. For
lung cancer, a tendency was noted for never-smoking
estimates to be high, significant for both the smoking-
adjusted data (P = 0.025) and the overall data (P =
0.029). This difference reflected the two high estimates
already noted in the sensitivity analysis.
Summary of meta-analyses for ST use in Western
populations
Table 30 brings together all the meta-analysis results for ST
use in Western populations. Based on smoking-adjusted
data, significant increases (P < 0.05) are seen for orophar-
yngeal cancer, though not based on studies published since
1990, and for prostate cancer, but not for any other cancer
considered. For neversmokers, significantincreasesareseen
for oropharyngeal cancer (again not when based on studies
published since 1990), for oesophageal cancer and also for
overall cancer. Compared with the smoking-adjusted
estimates, the estimates for never smokers tend to be more
variable, due to smaller numbers of ST-exposed cases
studied, though they consistently exceed 1.0.
Summary of meta-analyses for ST use in the USA
Table 31 similarly brings together the results for ST use
in the USA. With the exception of oesophageal cancer in
never smokers, significant increases seen in Table 28 are
again significant here, with an increase additionally seen
in the smoking-adjusted estimate for larynx cancer
(although based on only a single study).
Summary of meta-analyses for snuff use in Scandinavia
As shown in Table 32, the meta-analyses of results provide
overall effect estimates that, with one exception, are never
significantly increased and generally are close to 1.00. The
exception is for oesophageal cancer, where the marginally
significant increased RR seen in relation to snuff use for
never smokers (1.92, 1.00–3.68) derives solely from the
Swedish Construction Workers study [34]. In that study, no
increase was seen in smoking-adjusted analyses for the
whole population (1.00, 0.79–1.27). Unlike the corre-
sponding results for the USA, where meta-analysis esti-
mates are predominantly greater than 1.0, the estimates for
snuff as used in Scandinavia are as often below 1.0 as
above 1.0. Generally, the results do not suggest that snuff
as used in Scandinavia has any adverse effect on cancer risk.
Dose response data
Results relating the various cancers to dose of exposure
to ST are only reported in a few studies and are not
presented in detail here.
For oropharyngeal cancer, eight studies were identified that
related risk to extent and/or duration of exposure. In seven
ofthesestudies,whichallshownooverallrelationshipofST
with risk in Table 3[32,55,89-91,104,113], no significant
dose-response relationships are seen. It was only in one
study [61], that did show a clear overall relationship, that a
significant (P < 0.001)trendinrisk withincreasing duration
of exposure is seen, though only for cancers of the gum and
buccal mucosa, and not for other mouth and pharynx
cancers.
For other cancer sites relatively few studies report dose-
response data. In the CPS-II study [23] no trends with
durationorfrequencyareseenforeithertotalorlungcancer,
while in the Swedish Construction Workers study no trend
isseenforcutaneoussquamouscellcarcinomawithyearsof
snuff dipping [29] or for oral cancer or lung cancer with
daily amount of snuff consumed [32]. A significant trend
(P < 0.01) is reported with daily amount of snuffconsumed
Table 30: Summary of meta-analyses for smokeless tobacco use in Western populations
Overall data Smoking-adjusted data Never smokers
Cancer n RR/OR (95% CI) n RR/OR (95% CI) n RR/OR (95% CI)
Oropharyngeal (Table 4) 41 1.79 (1.36–2.36) 19 1.36 (1.04–1.77) 9 1.72 (1.01–2.94)
- (published since 1990) 18 1.28 (0.94–1.76) 14 1.00 (0.83–1.20) 7 1.24 (0.80–1.90)
Oesophageal (Table 6) 10 1.25 (1.03–1.51) 7 1.13 (0.95–1.36) 4 1.91 (1.15–3.17)
Stomach (Table 8) 9 1.03 (0.90–1.19) 8 1.03 (0.88–1.20) 4 1.27 (0.75–2.13)
Pancreatic (Table 10) 7 1.00 (0.68–1.47) 7 1.07 (0.71–1.60) 5 1.23 (0.66–2.31)
Any digestive (Table 12) 5 0.86 (0.59–1.25) 5 0.86 (0.59–1.25) 4 1.14 (0.99–1.33)
Larynx (Table 14) 5 1.43 (1.08–1.89) 2 1.34 (0.61–2.95) 0 -
Lung (Table 16) 9 0.96 (0.73–1.27) 6 0.99 (0.71–1.37) 5 1.34 (0.80–2.23)
Prostate (Table 18) 5 1.20 (1.03–1.40) 4 1.29 (1.07–1.55) 3 1.81 (0.76–4.30)
Bladder (Table 20) 14 1.00 (0.80–1.25) 10 0.95 (0.71–1.29) 6 1.10 (0.60–2.02)
Kidney (Table 22) 11 1.23 (0.86–1.76) 5 1.09 (0.69–1.71) 2 2.19 (0.63–7.70)
Non-Hodgkin's lymphoma (Table 24) 5 1.20 (0.83–1.75) 3 1.35 (0.62–2.95) 3 1.35 (0.62–2.95)
Overall cancer (Table 27) 7 0.98 (0.84–1.15) 7 0.98 (0.84–1.15) 6 1.10 (1.02–1.19)
n = number of estimates included in meta-analyses.
RR/OR = combined random-effects estimate based on RRs or ORs.
CI = confidence interval; OR = odds ratio; RR = relative risk.
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(page number not for citation purposes)for pancreatic cancer [32] in never smokers, but this merely
reflectstheoverallrelationship,withRRssimilarinlightand
heavyusers(1.9for1–9g/day,and2.1for10+g/dayrelative
to never users). For some of the case-control studies
considered [38,44,53,55,89,96,100,104,108,110,111,114],
dose-response resultsareavailable,but thesegenerally show
no significant trends. The only exceptions are a study of
kidney cancer [100] which reports a significant (P <0 . 0 5 )
trend for risk to increase with frequency of use of chewing
tobacco, and a study of pancreatic cancer [111] which
reportsa significant(P = 0.04) trend for risk toincreasewith
ounces per week (oz/wk) ST used, though with the odds
ratios forming an erratic pattern (1.0 for nonusers of
tobacco, 0.3 for ≤ 2.5 oz/wk ST and 3.5 for > 2.5 oz/wk ST).
Generally the rather sparse dose-response data add little to
the overall evidence.
Comparison of the effects of smoking and of ST use
Table 33 summarises the results of analyses comparing
the effects of smoking and of ST use, for seven smoking-
related cancers [127]. Overall in US men aged 35+ a total
of 142,205 deaths were seen from these cancers in 2005,
with lung cancer (63.4%) by far the most common.
Based on RRs from CPS-II for current and former
smoking [122] and estimates of the frequency of current
and former smoking [124] for US men of this age group,
the total number of deaths that would have occurred if
the men had the mortality rates of never smokers can be
estimated as 37,468, a reduction (E) of 104,737 deaths.
This reduction is proportionately largest for the cancers
most strongly associated with smoking (lung and
oropharynx), and least for those most weakly associated
(pancreas, kidney and bladder).
Table 31: Summary of meta-analyses for smokeless tobacco use in the USA
Overall data Smoking-adjusted data Never smokers
Cancer n RR/OR (95% CI) n RR/OR (95% CI) n RR/OR (95% CI)
Oropharyngeal (Table 4) 31 2.16 (1.55–3.02) 12 1.65 (1.22–2.25) 5 3.33 (1.76–6.32)
Oesophageal (Table 6) 6 1.56 (1.11–2.19) 3 1.89 (0.84–4.25) 3 1.89 (0.84–4.25)
Stomach (Table 8) 4 1.41 (0.95–2.10) 3 1.41 (0.93–2.12) 2 1.96 (0.82–4.70)
Pancreatic (Table 10) 5 0.86 (0.47–1.57) 5 0.99 (0.51–1.91) 3 1.09 (0.44–2.67)
Any digestive (Table 12) 5 0.86 (0.59–1.25) 5 0.86 (0.59–1.25) 4 1.14 (0.99–1.33)
Larynx (Table 14) 4 1.56 (1.21–2.00) 1 2.01 (1.15–3.51) 0 –
Lung (Table 16) 6 1.22 (0.82–1.83) 4 1.38 (0.72–2.64) 3 1.79 (0.91–3.51)
Prostate (Table 18) 5 1.23 (1.03–1.40) 4 1.29 (1.07–1.55) 3 1.81 (0.76–4.30)
Bladder (Table 20) 9 1.11 (0.85–1.45) 6 1.24 (0.83–1.85) 5 1.25 (0.69–2.26)
Kidney (Table 22) 8 1.52 (0.94–2.46) 3 1.41 (0.64–3.10) 1 4.80 (1.18–19.56)
Non-Hodgkin's lymphoma (Table 24) 3 1.45 (0.81–2.59) 2 2.07 (0.70–6.13) 2 2.07 (0.70–6.13)
Overall cancer (Table 27) 5 0.95 (0.74–1.22) 5 0.95 (0.74–1.22) 4 1.10 (1.01–1.20)
n = number of estimates included in meta-analyses.
RR/OR = combined random-effects estimate based on RRs or ORs.
CI = confidence interval; OR = odds ratio; RR = relative risk.
Table 32: Summary of meta-analyses for snuff as used in Scandinavia
Overall data* Never smokers
Cancer (source) n RR/OR (95% CI) N RR/OR (95% CI)
Oropharyngeal (Table 4) 7 0.97 (0.68–1.37) 4 1.01 (0.71–1.45)
Oesophageal (Table 6) 4 1.10 (0.92–1.33) 1 1.92 (1.00–3.68)
Stomach (Table 8) 5 0.98 (0.82–1.17) 2 0.90 (0.35–2.30)
Pancreatic (Table 10) 2 1.20 (0.66–2.20) 2 1.61 (0.77–3.34)
Larynx (Table 14) 1 0.90 (0.50–1.50) 0 -
Lung (Table 16) 2 0.71 (0.66–0.76) 2 0.82 (0.52–1.28)
Bladder (Table 20) 1 0.83 (0.62–1.11) 0 -
Kidney (Table 22) 1 0.72 (0.44–1.18) 0 -
Non-Hodgkin's lymphoma (Table 24) 2 1.04 (0.54–1.98) 1 0.77 (0.59–1.01)
Overall cancer (Table 27) 2 1.03 (0.91–1.16) 2 1.10 (0.94–1.29)
* all individual estimates included in these meta-analyses are smoking-adjusted or for never smokers except for one for non-Hodgkin's lymphoma.
n = number of estimates.
RR/OR = combined random-effects estimate based on RRs or ORs.
CI = confidence interval; OR = odds ratio; RR = relative risk.
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from Table 30 are then used to estimate the number of
deaths that would have occurred if the population were
never smokers, with ST use either at the same frequency
as for current and former smoking combined, 53%, or at
100%. In the first situation, the number of cancer deaths
rises from 37,468 to 38,570, an increase of 1,102; in the
second situation, it rises to 39,548, an increase of 2,081.
These numbers of cancers associated with ST use form,
r e s p e c t i v e l y ,1 . 1 %a n d2 . 0 % ,o fE ,t h en u m b e ra s s o c i a t e d
with smoking.
Discussion
Estimating the effects of ST use
We have analysed data relating cancer risk to the consump-
tion of chewing tobacco and snuff as used in Western
countries. We have identified 12 cancers (or combined
categories) where, as shown in Table 30, it is possible to
derive a (random-effects) meta-analysis estimate based on
at least five individual independent estimates.
It is notable that no strong association at all is evident
and that few of the associations are significant at
P < 0.05. Indeed, based on smoking-adjusted data,
which might be argued to provide a good compromise
between avoidance of bias and loss of power, only the
estimates for oropharyngeal and prostate cancer are
significant, with that for oropharyngeal cancer not
evident in more recently published studies. However, it
s h o u l db en o t e dt h a tw h i l em a n yo ft h ee s t i m a t e si n
Table 30 for never smokers have wide confidence limits,
and only those for oropharyngeal and oesophageal
cancer and for overall cancer are significant, all the
estimates are in fact greater than 1.00. Although
publication bias may be relevant, and more data are
clearly needed, the consistency of these findings suggests
that ST may increase the risk of cancer, though any effect
is likely to be quite weak. The results in Table 32 suggest,
however, that whether smoking-adjusted data or data for
never smokers are considered, there is little or no
evidence of an effect of snuff as used in Scandinavia.
There are a number of difficulties in interpreting the
results of these meta-analyses. The studies are of varying
design, size and quality. Many of the individual study
reports have limitations and present less information
Table 33: Comparison of effects of smoking and smokeless tobacco on smoking-related cancer
a in US males aged 35+
Oropharynx Oesophagus Pancreas Larynx Lung Bladder Kidney Total
Number of deaths (Di)
b 5,224 10,578 16,105 2,980 90,096 9,181 8,041 142,205
Relative risks
c
Current cigarette smoking (Rci) 27.48 7.60 2.14 10.48 22.36 2.86 2.95
Former cigarette smoking (Rfi) 8.80 5.83 1.12 5.24 9.36 1.90 1.95
Deaths if all the population were never smokers (Di*)
d 567 2,681 12,524 679 10,901 5,445 4,671 37,468
Deaths eliminated if all the population were never smokers (E)
e 104,737
Relative risks
f
- any ST use (Rsi) 1.36 1.13 1.07 1.34 1.00
g 1.00
h 1.09
Deaths in a population of never smokers
i
Same % become ST users as were smokers (Di**) 676 2,866 12,988 801 10,901 5,445 4,894 38,570
100% of population become ST users (Di***) 772 3,029 13,400 910 10,901 5,445 5,091 39,548
Increase in deaths in a population of never smokers
j
Same % become ST users as were smokers (I1) 1,102
100% of population become ST users (I2) 2,081
aICD 10
threvision codes [127] used are oropharynx (C00–C14), oesophagus (C15), pancreas (C25), larynx (C32), lung (C33, C34), bladder (C67) and
kidney (C64–C66, C68).
bNumbers of deaths in 2005 from WHO [123]. Here and for other results, the entries in brackets correspond to the notation used in the methods
section.
cRelative risks from US Surgeon General's Report 1989 [122] Table 6 p 150, derived from CPS-II.
dDi* is calculated as shown in the methods section, assuming 21.8% of current smokers and 31.2% of former smokers, based on the National Health
Interview Survey 2005 [124].
eE=Σ (Di -D i*).
fRelative risks for any ST use, based on smoking-adjusted data, as given in Tables 4, 6, 8, 10, 16, 20 and 22 for the seven cancers shown.
gActually 0.99, but taken as 1.00 for the purposes of estimation.
hActually 0.95, but taken as 1.00 for the purposes of estimation.
iDi** and Di*** are calculated as shown in the methods section, assuming that 53.0% or 100.0% respectively of the population use ST.
jI1 = Σ (Di** - Di*), I2 = Σ (Di*** - Di*)
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(page number not for citation purposes)than is ideal for a meta-analysis. Shortcomings include
small numbers of cases, and in particular of cases
exposed to ST, lack of histological confirmation, lack
of division by cancer site, as well as an unclear
description of inclusion and exclusion criteria, details
of case and control selection, and methods of exposure
assessment. Furthermore, details such as the type of ST
used, and duration and frequency of use, are often not
considered. The products used vary by country and over
time, and increased risks seen in older studies for some
c a n c e r sm a yn o tr e f l e c tt h er i s k so fm o r em o d e r n
products, with reduced nitrosamine levels [128]. For
most cancers, the number of effect estimates available is
really too limited to allow a very detailed examination of
variation in risk by such factors as type of product used,
current or former use, country and sex. Though meta-
regressions have been attempted for a number of cancers,
they have not added materially to the interpretation,
partly because of the limited amount of data for some
cancers, and partly because of the number of apparently
outlying estimates, notably for oropharyngeal cancer.
A major problem is that many of the studies fail to adjust
for smoking and other important potential confounding
variables. Although recent major reviews [7,8] consider that
all the cancers considered in Table 30, with the exception
of prostate cancer and non-Hodgkin’sl y m p h o m a ,a r e
caused by smoking, it is evident that a number of the
studies do not provide estimates that are either for never
smokers or for smokers and non-smokers combined with
adjustment for smoking. Even where adjustment for
smoking is carried out, this is often by a relatively simple
approach, with no account taken of number of cigarettes
smoked or duration of smoking. Smokers who also use ST
may smoke fewer cigarettes a day than smokers who do
not. Failure to adjust for smoking is particularly common
for studies of oropharyngeal cancer, with many of the older
studies not taking smoking into account at all when
considering ST. The potential importance of this is
illustrated by the overall estimate for oropharyngeal cancer
being substantially reduced, from 1.79 to 1.36, when
attention is restricted to smoking-adjusted data.
A d j u s t m e n tf o ro t h e rr i s kf a c t o r si sa l s oi m p o r t a n t ,a s
shown by the case of oropharyngeal cancer where the
smoking-adjusted estimate of 1.36 (1.04–1.77, n = 19)
can be compared with the estimate adjusted for smoking
and alcohol of 1.07 (0.84–1.37, n = 10). Restricting
attention to estimates adjusted for both factors also
eliminated the highly significant (P < 0.001) hetero-
geneity seen in the smoking-adjusted data. Alcohol is
also an important factor in the aetiology of oesophageal,
larynx and liver cancer [8], but the number of ST effect
estimates adjusted both for smoking and alcohol for
these three cancers is very low indeed, respectively 2, 1
and 0. Other factors considered rarely, or not at all,
include, for example, Helicobacter pylori infection for
stomach cancer and diet for digestive cancer.
Another difficulty in interpreting the overall results is the
variability of the findings. Heterogeneity significant at least
at P < 0.05 is evident in the smoking-adjusted estimates for
cancers of the oropharynx (though not in the more recent
data), pancreas, larynx, lung and bladder, as well as for
overall cancer and overall digestive cancer. As noted above,
the evidence is too limited for most of the cancers to allow
a proper investigation of the sources of this heterogeneity.
Based on the data analysed, there is little or no evidence
of publication bias. However, it should be noted that the
number of studies reporting results in a form that cannot
be included in the meta-analyses is fairly high, repre-
senting up to about 30% for some cancers (see Tables 5,
7, 9, 13 and 17).
We are aware that the smoking-adjusted meta-analysis
estimates we report for oropharyngeal cancer (1.36, 95%
CI 1.04–1.77)), oesophageal cancer (1.13, 0.95–1.36),
pancreatic cancer (1.07, 0.71–1.60) and lung cancer
(0.99, 0.71–1.37) show much less evidence of a
relationship with ST than do corresponding estimates
recently reported in a review by Boffetta et al.[ 6 ]
(oropharynx: 1.8, 1.1–2.9; oesophagus: 1.6, 1.1–2.3;
pancreas: 1.6, 1.1–2.2; lung 1.2, 0.7–1.9). Reasons for
this, based on a detailed analysis of this review, will be
presented in a separate publication in BMC Cancer.
Comparison of the effects of smoking and ST use
In 2005 in US men aged 35 or over, there were a total of
142,205 deaths from seven cancers considered to be caused
by smoking. Based on relative risks from CPS-II for current
and former smoking [122] and estimates of the frequency
of current and former smoking [124] for US men of this
age group, we estimate that, had the population at risk the
mortality rates of never smokers, the numbers would have
reduced by 104,737, with the reduction in lung cancer
deaths, 79,195, a major contributor. Any increase in risk
resulting from the introduction of ST to a population of
never smokers would be very much less than this. Even
assuming that the smoking-adjusted meta-analysis esti-
mates for the seven cancers all reflect a true effect of ST, the
increase in deaths among a never-smoker population
would be by 1,102 if 53% of the population used ST
(the same proportion as had ever smoked) or by 2,081 if
the whole population did. These increases represent,
respectively, only 1.1% and 2.0% of the 104,737 deaths
attributed to cigarette smoking.
There are a number of objections that can be made in
respect of this comparison. These include the following:
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CPS-II, conducted in the 1980s, and may not reflect
those appropriate for 2005, given inter alia changes in
cigarettes that have occurred since then. However, CPS-II
is widely used as a source of data for calculating deaths
attributed to smoking (for example, [8,129]).
2. The RR estimates used for ST use are not specifically
for the USA, or for males. However, 62 of the 89 studies
considered in this review were conducted in the USA,
and 41 of the 58 estimates used in the smoking-adjusted
meta-analyses for the seven cancers are for males (with
12 for sexes combined and five for females).
3. The RR estimates used for ST are for any ST use, and do
not separate current and former use, due to most studies
not providing such data.
4. The calculations are limited to those seven cancers
which the US Surgeon General, in his 1989 report [122]
considered to be caused by smoking and for which RRs
were provided for CPS-II. A more recent report [8]
includes stomach cancer and leukaemia as caused by
smoking. For stomach cancer, the meta-analyses in
Table 6 showed virtually no association with ST use
(1.03, 0.88–1.20, n = 8), while the more limited data
for leukaemia also showed no clear evidence of a
relationship.
5. It is theoretically possible that ST use might increase
the risk of some cancers not increased by smoking. Here
one should note the significant association for prostate
cancer (1.29, 1.07–1.55).
6. The calculations do not take into account the fact that
a proportion of US males aged 35+ already use ST. Given
the relatively weak association between cancer and ST
use, any attempt to do this would have had relatively
little effect.
7. The calculations also do not take pipe and cigar
smoking into account.
8. The approach used is somewhat simplistic, and a more
realistic (but more complex) calculation might be to
compare predicted cancer deaths over a long-term period
in a population continuing to smoke as at present, with
the predicted number in a population switching from
cigarettes to ST.
Despite all these points, it is clear that any effect of ST on
r i s ko fc a n c e r ,i fi te x i s t sa ta l l ,i sq u a n t i t a t i v e l yv e r y
much smaller than the known effects of smoking. This is
in any case apparent from a simple comparison of the
RRs for cigarette smoking and for ST use.
Conclusion
The available data relating to ST use have a number of
weaknesses, including inadequate control for smoking in
many, and limited data for never smokers. Nevertheless, it
is possible to conduct meta-analyses based on smoking-
adjusted estimates for a relatively wide range of cancers.
These show no indication of an increased risk of cancer for
snuff, as used in Scandinavia. The overall data for
oropharyngeal cancer shows a significant increase in risk
associated with ST use, but this is not evident for estimates
adjusted for smoking and alcohol, or for studies published
since 1990. Any effect of ST may relate mainly to products
used in the past in the USA. A weak but significant
association with prostate cancer, based on limited data
from US studies, requires more confirmatory evidence.
Reports of significant associations with pancreatic and
oesophageal cancer in an earlier review [6] are not
confirmed, and reasons for this will be discussed in a
later publication. Risk from ST products as used in North
America and Europe is clearly very much less than that
from smoking, and is not evident at all in Scandinavia.
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